<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0809211024
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2013
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        AUGMENTIN 228 MG-5ML SUSPENSION
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        AMOXICILLIN,CLAVULANIC ACID
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        200,28.5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Suspension
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        70
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        19.20
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="SMIITHKLINE BEECHAM" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            SMIITHKLINE BEECHAM
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 1182]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            GLAXO SAUDI ARABIA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            GLAXO SAUDI ARABIA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01CR02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Augmentin is an antibiotic used in adults and children to treat infections in different parts of the body caused by certain types of bacteria.</p><p>Augmentin contains two different medicines called amoxicillin and clavulanic acid. Amoxicillin is a penicillin antibiotic. Amoxicillin can sometimes be stopped from working (made inactive). The other active medicine, clavulanic acid, stops this from happening.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Don&rsquo;t take Augmentin <!--[if supportFields]><span style='mso-element:
field-begin'></span><span style='mso-spacerun:yes'> </span>DOCVARIABLE
vault_nd_ebd6237a-93a4-420d-a6de-06ac6edd6853 \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you&rsquo;re <strong>allergic</strong> (<em>hypersensitive</em>) to amoxicillin, clavulanic acid, other penicillin based antibiotics, or similar antibiotics called cephalosporins.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have ever had <strong>liver problems</strong> or <strong>jaundice </strong>(<em>yellowing of the skin and/or whites of the eyes</em>) when taking an antibiotic.</p><p>&egrave; if you think any of these apply to you, <strong>check with your doctor</strong> before you take Augmentin.</p><p>Take special care with Augmentin<!--[if supportFields]><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_781b4ecc-59b9-42e6-994e-fc44a55188a3 \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p>Before you take Augmentin your doctor needs to know:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have ever had an <strong>allergic</strong> <strong>reaction</strong> to any other antibiotics or medicines. This might include a skin rash or swelling of the face or neck.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have <strong>glandular fever </strong>(<strong>mononucleosis</strong>)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you&rsquo;re taking medicines, such as warfarin, that are used to <strong>prevent blood clots</strong></p><p>&bull; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have liver problems &bull; if you have kidney disease<!--[if supportFields]><span style='font-weight:normal'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_b74da703-30c4-4a2e-81c4-c7f65982a659 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-weight:normal'><span style='mso-element:field-end'></span></span><![endif]--></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you&rsquo;re not <strong>urinating</strong> <strong>regularly </strong>or not able to <strong>drink</strong> very much.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a genetic condition called phenylketonuria (<strong><em>see also &lsquo;Augmentin contains aspartame&rdquo;</em></strong><em> later in Section 2)</em></p><p>&egrave; <strong>Check with your doctor</strong> if you think any of these may apply to you. Your doctor will decide whether Augmentin is suitable for you and may need to adjust your dose or give you a different medicine.<strong> </strong></p><p>Look out for important symptoms <!--[if supportFields]><span
style='mso-element:field-begin'></span><span
style='mso-spacerun:yes'> </span>DOCVARIABLE
vault_nd_17870637-9a61-4568-9a79-9bdfe9f143aa \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p>Augmentin can make some existing conditions worse, or cause serious side effects, such as <strong>severe allergic reactions, serious skin reactions, chest pain, </strong><strong>repetitive vomiting within 1 to 4 hours of Augmentin administration, serious liver problems or severe diarrhoea </strong>or<strong> inflammation of the large intestines (pseudomembranous colitis)</strong>.</p><p>You must look out for certain symptoms while you&rsquo;re taking Augmentin to help reduce the risk of any problems. See &lsquo;<em>Look out for important symptoms</em>&rsquo; in <strong>Section 4</strong>.</p><p>While you&rsquo;re taking Augmentin <!--[if supportFields]><span
style='mso-element:field-begin'></span><span
style='mso-spacerun:yes'> </span>DOCVARIABLE
vault_nd_21d0f2ca-1e3a-413d-af7b-02b813e0091c \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p>Other medicines and Augmentin <!--[if supportFields]><span
style='mso-element:field-begin'></span><span
style='mso-spacerun:yes'> </span>DOCVARIABLE
vault_nd_03942427-d7f7-4cd5-8207-e5863e166275 \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p><strong>Tell your doctor or pharmacist if you&#39;re taking any other medicines</strong>, if you&rsquo;ve taken any recently, or if you start taking new ones. This includes medicines bought without a prescription.</p><p>Some medicines may affect how<strong><em> </em></strong>Augmentin works, or make it more likely that you&rsquo;ll have side effects. Augmentin can also affect how some other medicines work. These include:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>probenecid</strong> and <strong>allopurinol</strong> (used to <strong>treat gout</strong>).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>anticoagulants</strong> (used to <strong>prevent blood clots</strong>) such as warfarin and acenocoumarol.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>mycophenolate</strong> <strong>mofetil</strong> (used to <strong>prevent the rejection of transplanted organs</strong>).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; methotrexate (used to treat conditions such as cancer and severe psoriasis).</p><p>&egrave; Tell your doctor or pharmacist if you&rsquo;re taking any of these.</p><p>Augmentin may reduce how well the <strong>contraceptive pill</strong> works. If you&rsquo;re taking the contraceptive pill while you&rsquo;re being treated with Augmentin, you should also use a <strong>barrier method of contraception</strong> (such as condoms). Ask your doctor for advice.</p><p>&nbsp;</p><p>Pregnancy and breast-feeding <!--[if supportFields]><span
style='mso-element:field-begin'></span><span
style='mso-spacerun:yes'> </span>DOCVARIABLE
vault_nd_c598216f-916d-4322-a86b-19d8ffc25747 \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p>If you&rsquo;re <strong>pregnant</strong>, or <strong>think you could be</strong>, or if you&rsquo;re <strong>planning to become pregnant</strong>, <strong>don&rsquo;t take Augmentin</strong> without checking with your doctor. <strong>Your doctor</strong> will consider the benefit to you and the risk to your baby of taking Augmentin while you&rsquo;re pregnant.</p><p>You can usually breast-feed while you&rsquo;re taking Augmentin. If you&rsquo;re breast-feeding or considering breast-feeding, <strong>check with your doctor before you take Augmentin</strong>.</p><p><strong>&nbsp;</strong></p><p>Augmentin contains aspartame <!--[if supportFields]><span
style='mso-element:field-begin'></span><span
style='mso-spacerun:yes'> </span>DOCVARIABLE
vault_nd_1418881b-0ed9-42e6-8780-de2730e82c9e \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p>Augmentin contains <strong>aspartame</strong>, which is a source of phenylalanine. If you have an intolerance to aspartame or have a condition called <strong>phenylketonuria (PKU)</strong>:</p><p>&egrave; <strong>Check with your doctor </strong>that Augmentin is right for you.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take Augmentin exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p><strong>How much to take&nbsp; </strong></p><p>Your doctor will decide on the correct dosage for you</p><p>Patients with kidney or liver problems<!--[if supportFields]><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_87ea452c-4768-44dc-ad7d-e4560969afcf \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have kidney problems, your doctor may give you a different strength or a different medicine.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have liver problems, you may have more frequent blood tests to check how your liver is working.</p><p>How to take <!--[if supportFields]><span
style='mso-element:field-begin'></span><span
style='mso-spacerun:yes'> </span>DOCVARIABLE
vault_nd_62527f94-b6f1-4ab0-a78c-56a9a4323487 \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take Augmentin at the start of a meal or slightly before.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Instructions on how to prepare Augmentin suspension are provided at the end of this leaflet.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shake the bottle well before taking each dose.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A dosing syringe, spoon or cup may be supplied with the pack, which you can use to measure the dose accurately.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A dosing syringe should be used to give the correct dose to children below 3 months. Instructions on how to use the dosing syringe are provided at the end of this leaflet.</p><p>&nbsp;</p><p>Do not take Augmentin for more than 14 days. If you still feel unwell you should go back to <strong>see your doctor</strong></p><p>&nbsp;</p><p>If you forget to take Augmentin <!--[if supportFields]><span
style='mso-element:field-begin'></span><span
style='mso-spacerun:yes'> </span>DOCVARIABLE
vault_nd_64f7673d-7c3f-49fa-92b6-dcd487988ae2 \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p><strong>Don&#39;t take a double dose to make up for a missed dose</strong>. Just take it as soon as you remember.</p><p><strong>If you&rsquo;re not sure what to do,</strong> ask your doctor or pharmacist.</p><p>If you take too much Augmentin <!--[if supportFields]><span
style='mso-element:field-begin'></span><span
style='mso-spacerun:yes'> </span>DOCVARIABLE
vault_nd_f64ca803-65c9-4052-84ba-a67a5b9c2b29 \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p>If you accidently take<em> </em>too much Augmentin, it is unlikely to cause any serious problems. The most common side effects of taking too much Augmentin are nausea, vomiting and diarrhoea.</p><p>If you&rsquo;re worried, or you feel unwell:</p><p>&egrave;Ask your doctor or pharmacist for advice.</p><p>Don&rsquo;t stop taking Augmentin without advice <!--[if supportFields]><span
style='mso-element:field-begin'></span><span
style='mso-spacerun:yes'> </span>DOCVARIABLE
vault_nd_fdf5a7d1-56dd-4de6-80b9-e0233edec18f \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p><strong>It is important that you take the full course of Augmentin</strong>. Don&rsquo;t stop unless your doctor advises you to &ndash; even if you&rsquo;re feeling better. If you don&rsquo;t complete the full course of treatment, the infection may come back.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Augmentin can cause side effects, but not everybody gets them.&nbsp;</p><p>Look out for important symptoms<!--[if supportFields]><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_766b52f7-5af5-413a-b0eb-6a07809f4246 \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p>&nbsp;Severe allergic reactions<!--[if supportFields]><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_c64add47-6a14-49c3-99e6-e0823040f8af \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p>These are very rare in people taking Augmentin. Signs include:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; raised, itchy rash (<em>hives</em>)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of blood vessels (<em>vasculitis</em>) which may be visible as red or purple raised spots on the skin, but can affect other parts of the body</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever, joint pain, swollen glands in the neck, armpit or groin</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling, sometimes of the face or mouth (<em>angioedema</em>), which may cause difficulty in swallowing or breathing</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; collapse.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chest pain which can be a sign of a potentially serious allergic reaction called <em>Kounis syndrome</em>.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; repetitive vomiting (1 to 4 hours after Augmentin administration), stomach pain, abnormal drowsiness, diarrhoea and low blood pressure which can be a sign of a serious allergic reaction called <em>drug-induced enterocolitis syndrome</em>.</p><p>&egrave; <strong>Get medical help immediately</strong> if you get any of these symptoms. <strong>Stop taking Augmentin.</strong></p><p>Serious skin reactions<!--[if supportFields]><span
style='mso-element:field-begin'></span> DOCVARIABLE vault_nd_d7408f89-550e-42b0-ab9b-c82cd4285839
\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p>These are rare in people taking Augmentin. Signs include:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin rash, which may blister, and looks like small targets (central dark spots surrounded by a paler area, with a dark ring around the edge &ndash; <em>erythema multiforme</em>).</p><p>These are very rare in people taking Augmentin. Signs include:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a widespread rash with blisters and peeling skin, particularly around the mouth, nose, eyes, and genitals (<em>Stevens-Johnson syndrome</em>), and a more severe form, causing blisters and peeling skin on much of the body surface (<em>toxic epidermal necrolysis</em>)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a widespread, red, skin rash with small blisters containing pus (<em>exanthemous pustulosis</em>)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a red, itchy, scaly rash with blisters and bumps under the skin (<em>bullous exfoliative dermatitis</em>)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; flu-like symptoms with a rash, fever, swollen glands, and abnormal blood test results (including white blood cells (<em>eosinophilia</em>) and liver enzymes) (<em>Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS))</em>.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a red rash commonly seen on both sides of buttocks, upper inner thighs, armpits, neck (Symmetrical Drug-related Intertriginous and Flexural Exanthema (SDRIFE)).</p><p>&nbsp;</p><p>&egrave; <strong>Get medical help immediately </strong>if you get any of these symptoms<strong>. Stop taking Augmentin.</strong></p><p>Serious liver problems<!--[if supportFields]><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_81079ec2-f867-465c-b3cf-1f1eec11d31e \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p>On rare occasions, medicines like Augmentin can cause liver problems, causing yellowing of the skin and/or whites of the eyes.</p><p>&egrave;Tell your doctor as soon as possible if you get any of these symptoms.</p><p><strong>Severe diarrhoea (<em>Pseudomembranous colitis</em>) </strong></p><p>On rare occasions, medicines like Augmentin can cause inflammation of the colon (large intestine), causing diarrhoea, usually with blood and mucus, stomach pain and fever.</p><p>&egrave;Tell your doctor as soon as possible if you get any of these symptoms.</p><p>Very common side effects <!--[if supportFields]><span
style='mso-element:field-begin'></span><span
style='mso-spacerun:yes'> </span>DOCVARIABLE
vault_nd_c98443be-b656-4d96-bf55-1f2aca59a3a1 \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p>These may affect <strong>more than 1 in 10</strong> people:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea (in adults). <strong>Common side effects&nbsp; </strong></p><p>These may affect <strong>up to 1 in 10 </strong>people:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; thrush (fungal infection caused by <em>Candida</em> in the vagina, mouth or skin folds)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sick (<em>nausea</em>)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vomiting</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea (in children). <strong>Uncommon side effects&nbsp; </strong></p><p>These may affect <strong>up to 1 in 100</strong> people:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dizziness</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; indigestion</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin rash</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itching</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itchy, bumpy rash (<em>hives</em>)</p><p>&nbsp;</p><p>&nbsp;</p><p>Uncommon side effects that may show up in blood tests are:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase in some substances (enzymes) produced by the liver</p><p><strong>Rare side effects&nbsp; </strong></p><p>These may affect <strong>up to 1 in 1,000</strong> people:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin rash, which may blister, and looks like small targets (central dark spots surrounded by a paler area, with a dark ring around the edge &ndash; <em>erythema multiform</em>e)</p><p>(See <em>&lsquo;serious skin reactions&rsquo;</em> earlier in Section 4) Rare side effects that may show up in blood tests are:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decrease in the number of white blood cells (<em>leucopenia</em>, including <em>neutropenia)</em></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decrease in the number of cells that help blood to clot (<em>thrombocytopenia</em>)</p><p><strong>Very rare side effects&nbsp; </strong></p><p>These may affect <strong>up to 1 in 10,000</strong> people:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe allergic reactions (<em>See also <strong>&lsquo;severe allergic reactions&rsquo;</strong> earlier in Section 4</em>)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; serious skin reactions (<em>See also <strong>&lsquo;serious skin reactions&rsquo;</strong> earlier in Section 4</em>)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the liver (<em>hepatitis</em>) (<em>See also <strong>&lsquo;serious liver problems&rsquo;</strong> earlier in Section 4</em>)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; yellowing of the whites of the eyes or skin (<em>jaundice</em>) (<em>See also <strong>&lsquo;serious liver problems&rsquo;</strong> earlier in Section 4</em>)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the large intestines (<em>See also <strong>&lsquo;severe diarrhoea&rsquo;</strong> earlier in Section 4</em>)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the kidney (<em>nephritis</em>)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an increase in the time blood takes to clot</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; being unusually active (<em>hyperactivity</em>)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fits (<em>seizures</em>)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; black tongue which looks hairy<strong><em> </em></strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the protective membrane surrounding the brain (aseptic meningitis)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash with blisters arranged in a circle with central crusting or like a string of pearls (<em>linear IgA disease</em>).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stained teeth that can usually be removed by brushing</p><p>&nbsp;</p><p>Very rare side effects that may show up in blood or urine tests are:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe decrease in the number of white blood cells (<em>agranulocytosis</em>)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; red blood cells destroyed too quickly (<em>haemolytic anaemia</em>)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; crystals in urine</p><p>&egrave; <strong>Tell your doctor or pharmacist</strong> if any of the side effects listed becomes <strong>severe or</strong> <strong>troublesome</strong>, or if you notice any side effects not listed in this leaflet.<strong> </strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the sight and reach of children.</p><p>Do not take Augmentin after the expiry date shown on the pack.</p><p>Store in a dry place in the original packaging at below 25C.</p><p>Once made up, the suspension should be stored in a refrigerator (2&deg;C to 8&deg;C).</p><p>Do not freeze.</p><p>Dispose of any unused suspension 7 days after first making up.</p><p>Don&rsquo;t dispose of medicines in waste water or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Augmentin 228mg &amp; 457mg suspensions contains<!--[if supportFields]><span
style='font-weight:normal'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_3a41c235-f741-4de0-96f1-0b8219298ead \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-weight:normal'><span style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p><p>The active substances are amoxicillin and clavulanic acid.</p><p>Each 5 mL of reconstituted suspension contains either:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; amoxicillin trihydrate equivalent to 200 mg amoxicillin and potassium clavulanate equivalent to 28.5 mg clavulanic acid</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; amoxicillin trihydrate equivalent to 400 mg amoxicillin and potassium clavulanate equivalent to 57 mg clavulanic acid</p><p>The other ingredients are:</p><p>Xanthan gum, hydroxypropylmethylcellulose, colloidal silica, succinic acid, silicon dioxide, raspberry, orange &ldquo;1&rdquo;, orange &ldquo;2&rdquo;, golden syrup dry flavours, aspartame.</p><p><strong>&nbsp;</strong></p><p>What Augmentin suspension looks like and contents of the pack<!--[if supportFields]><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_b35672cb-0fdd-4d31-a78e-80e4d4725c16 \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p><em>&nbsp;</em></p><p>Augmentin powder for oral suspension is available in bottles; each glass bottle contains a white to off-white powder. The powder needs to be reconstituted with water before oral administration. The powder in each bottle provides either:</p><p>200mg of amoxicillin and 28.5 mg of clavulanic acid per 5 mL or 400mg of amoxicillin and 57 mg of clavulanic acid per 5 mL, when reconstituted as recommended.</p><p>The reconstituted powder for oral suspension has an off-white colour and mixed fruit flavour.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Step-by-step instructions/Information for healthcare professionals<!--[if supportFields]><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_78ea1138-1b49-49cf-89b0-26de8ee15941 \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p>For bottles with aluminium screw caps, check the cap ring seal is intact before using. Alternatively, for bottles with a plastic child-resistant cap, check the foil-backed bottle seal is intact before using.</p><p>At time of use, the dry powder should be reconstituted to form an oral suspension, as detailed below:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Invert and shake bottle to loosen powder.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Add volume of water (indicated below). Invert and shake well</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Alternatively, fill the bottle with water to just below the mark on bottle label.</p><p>Invert and shake well, then top up with water to the mark. Invert and shake again.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allow to stand for 5 minutes to ensure full dispersion.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shake well before taking each dose.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:605px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong><em>AUGMENTIN suspension 228 mg/5 mL</em> </strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Fill Weight (g) </strong></p></td><td style="vertical-align:top"><p><strong>Volume of water to be added to reconstitute (mL) </strong></p></td><td style="vertical-align:top"><p><strong>Final volume of reconstituted oral suspension (mL) </strong></p></td></tr><tr><td style="vertical-align:top"><p>7.7&nbsp;</p></td><td style="vertical-align:top"><p>64&nbsp;</p></td><td style="vertical-align:top"><p>70&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>15.4&nbsp;</p></td><td style="vertical-align:top"><p>128&nbsp;</p></td><td style="vertical-align:top"><p>140&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:605px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong><em>AUGMENTIN suspension 457 mg/5 ml</em> </strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Fill Weight (g) </strong></p></td><td style="vertical-align:top"><p><strong>Volume of water to be added to reconstitute (mL) </strong></p></td><td style="vertical-align:top"><p><strong>Final volume of reconstituted oral suspension (mL) </strong></p></td></tr><tr><td style="vertical-align:top"><p>6.3&nbsp;</p></td><td style="vertical-align:top"><p>31&nbsp;</p></td><td style="vertical-align:top"><p>35&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>12.6&nbsp;</p></td><td style="vertical-align:top"><p>62&nbsp;</p></td><td style="vertical-align:top"><p>70&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>25.2&nbsp;</p></td><td style="vertical-align:top"><p>124&nbsp;</p></td><td style="vertical-align:top"><p>140&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>The AUGMENTIN suspension 457 mg/5 ml and 228 mg/5 mL presentations may be provided with a dosing device.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                The AUGMENTIN suspension 457 mg/5 ml and 228 mg/5 mL presentations may be provided with a dosing device. 
 
Not all packs are available in all countries 
Augmentin is owned by or licensed to the GSK group of companies © 2023 GSK, all rights reserved. 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Manufacturing:</strong></p><p>Glaxo Wellcome Production*, Mayenne, France</p><p><strong>Packing:</strong></p><p>Glaxo Saudi Arabia Ltd.* Jeddah, KSA</p><p>Marketing Authorisation Holder <!--[if supportFields]><span style='font-weight:normal'><span
style='mso-element:field-begin'></span><span
style='mso-spacerun:yes'> </span>DOCVARIABLE
vault_nd_6498d6fc-170c-49e9-ad23-9bb8c6aee97b \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-weight:normal'><span style='mso-element:field-end'></span></span><![endif]--></p><p>Glaxo Saudi Arabia Ltd.* Jeddah, KSA</p><p>*member of the GSK group of companies</p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p><strong>For any information about this medicinal product, please contact:</strong></p><p><strong>GSK - Head Office, Jeddah</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tel:&nbsp; +966-12-6536666</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mobile: +966-56-904-9882</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Email: gcc.medinfo@gsk.com</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://gskpro.com/en-sa/</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; P.O. Box 55850, Jeddah 21544, Saudi Arabia</p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p><strong>To report any side effect(s):</strong></p><p><strong><em>Kingdom of Saudi Arabia</em></strong></p><p><strong>-National Pharmacovigilance centre (NPC)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reporting Hotline: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa</p><p><strong>-GSK - Head Office, Jeddah</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tel:&nbsp; +966-12-6536666</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mobile: +966-56-904-9882</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Email: saudi.safety@gsk.com</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://gskpro.com/en-sa/</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; P.O. Box 55850, Jeddah 21544, Saudi Arabia</p><p>&nbsp;</p><p>THIS IS A MEDICAMENT<!--[if supportFields]><span style='font-size:10.5pt;mso-bidi-font-size:
11.0pt;line-height:110%;font-family:"Arial",sans-serif;mso-fareast-font-family:
Arial;font-weight:normal'><span style='mso-element:field-begin'></span>
DOCVARIABLE VAULT_ND_207af460-2202-4757-ab48-c344f460f855 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:10.5pt;mso-bidi-font-size:11.0pt;line-height:110%;font-family:
"Arial",sans-serif;mso-fareast-font-family:Arial;font-weight:normal'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>-&nbsp; Medicament is a product which affects your health, and its consumption contrary to&nbsp;&nbsp;&nbsp;&nbsp; instructions is dangerous for you.</p><p>-&nbsp; Follow strictly the doctor&rsquo;s prescription, the method of use and the instructions of the&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pharmacist who sold the medicament.</p><p>-&nbsp; The doctor and the pharmacist are experts in medicine, its benefits and risks.</p><p>-&nbsp; Do not by yourself interrupt the period of treatment prescribed for you.</p><p>-&nbsp; Do not repeat the same prescription without consulting your doctor.</p><p>-&nbsp; Keep all medicine out of reach of children</p><p>Council of Arab Health Ministers Union of Arab Pharmacists</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Version Number: GDS29 
Version Date: 07 September2023


            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">أوجمنتين هو مضاد حيوي يتناوله البالغون والأطفال لعلاج الالتهابات في الأجزاء المختلفة من الجسم التي تسببها أنواع معينة من البكتيريا .</p><p dir="RTL">يحتوي أوجمنتين على مادتين مختلفتين، هما: الأموكسيسيلين وحمض الكلاڨيولانيك. الأموكسيسيلين هو مضاد حيوي يحتوي على بنسلين .</p><p dir="RTL">يمكن أحيانًا مقاومة الأموكسيسيلين )جعله غير فعال(، لذا تساعد المادة الفعالة الأخرى -حمض الكلاڨيولانيك - على منع بعض البكتريا من أن تصبح مقاومة للأموكسيسيلين.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول أوجمنتين إذا:&nbsp; </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من حساسية )حساسية شديدة) تجاه الأموكسيسيلين، أو حمض الكلاڨيولانيك، أو المضادات الحيوية الأخرى القائمة على البنسلين، أو المضادات الحيوية المماثلة التي تسمى السيفالوسبورينات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من مشاكل بالكبد أو اليرقان )اصفرار الجلد و/ أو بياض العين) عند تناول المضاد الحيوي.</p><p dir="RTL">&ccedil;إذا انطبق عليك أي مما سبق، تحدث إلى طبيبك قبل تناول أوجمنتين.</p><p dir="RTL"><strong>الاحتياطات الخاصة التي يجب مراعاتها عند تناول أوجمنتين&nbsp; </strong></p><p dir="RTL">تحدث إلى طبيبك قبل تناول أوجمنتين إذا:</p><p dir="RTL">تعرضت من قبل <strong>لرد فعل تحسسي</strong> تجاه أي مضادات حيوية أو أدوية أخرى، وقد يشمل ذلك الطف ح الجلدي أو تورم الوجه أو الرقبة.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان لديك <strong>حمى غُدِّيّة </strong><strong>)</strong><strong>كثرة الوحيدات العدوائية).</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تتناول الأدوية -مثل وارفارين- التي تستخدم <strong>لمنع تجلط الدم. </strong>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من <strong>مشاكل بالكبد</strong>.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من <strong>مرض بالكلى. </strong>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت لا <strong>تتبول بانتظام</strong> أو لا تستطيع <strong>الشرب</strong> بكثرة.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان لديك حالة وراثية تسمى بيلة الفينيل كيتون )<strong>انظر أيضا &quot;أوجمنتين يحتوي على أسبارتام&quot;</strong> لاحًقا في القسم 2 )</p><p dir="RTL">&ccedil; <strong>تحدث إلى طبيبك</strong> إذا انطبق عليك أي مما سبق. سيقرر طبيبك ما إذا كان أوجمنتين مناسبًا لك وقد تحتاج إلى تعديل جرعتك إو إعطائك دواءً مختلفًا.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>انتبه إلى الأعراض المهمة&nbsp; </strong></p><p dir="RTL">يمكن أن يجعل أوجمنتين بعض الحالات الحالية أسوأ أو يسبب آثارًا جانبية خطيرة، مثل: <strong>ردود الفعل&nbsp; التحسسية الشديدة، أو التفاعلات الجلدية الخطيرة،&nbsp; أوألم الصدر، أو أمراض الكبد الخطيرة،</strong><strong> </strong><strong>القيء المتكرر خلال ساعة إلى 4 ساعات من تلقي دواء أوجمنتين</strong></p><p dir="RTL"><strong>&nbsp;أو الإسهال الشديد، أو التهاب الأمعاء الغليظة</strong> <strong>)</strong><strong>التهاب القولون الغشائي الكاذب)</strong>. يجب&nbsp; أن تنتبه إلى بعض الأعراض أثناء تناولك أوجمنتين للمساعدة في تقليل مخاطر حدوث أي مشكلات . انظر &quot;انتبه إلى الأعراض المهمة&quot; في <strong>القسم </strong><strong>4</strong>.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أثناء تناول أوجمنتين&nbsp; </strong></p><p dir="RTL"><strong>تفاعلات أوجمنتين مع الأدوية الأخرى&nbsp; </strong></p><p dir="RTL"><strong>يرجى إبلاغ طبيبك أو الصيدلي إذا كنت تتناول</strong> أو قد تناولت مؤخراً <strong>أي أدوية أخرى</strong> أو إذا بدأت في تناول أدوية جديدة، ويشمل ذلك تلك التي حصلت عليها دون وصفة طبية.</p><p dir="RTL">قد تؤثر بعض الأدوية على طريقة عمل أوجمنتين أو تزيد من احتمالية الإصابة بآثار جانبية . يمكن أن يؤثر أوجمنتين أيضًا على كيفية عمل بعض الأدوية الأخرى. ويشمل ذلك ما يلي :</p><p dir="RTL">&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>البروبينسيد</strong> و<strong>الألوپيورينول</strong> )يستخدمان <strong>لعلاج النقرس</strong>).&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>مضادات التخثر</strong> ) تستخدم <strong>لمنع تجلط الدم</strong>) مثل وارفارين وأسينوكومارول.&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>ميكوفينولات موفيتيل</strong> ) يستخدم <strong>لمنع رفض الأعضاء المزروعة)</strong>.</p><p dir="RTL">&bull; ميثوتريكسات )يستخدم لعلاج حالات مثل السرطان والصدفية الشديدة).</p><p dir="RTL">&ccedil;&nbsp;&nbsp; يرجى إبلاغ طبيبك أو الصيدلي إذا كنت تتناول أي مما سبق</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يقلل أوجمنتين من مدى فاعلي ة <strong>حبوب منع الحمل</strong>. إذا كنت&nbsp; تستخدمين حبوب منع الحمل أثناء تناولك أوجمنتين، فيجب عليك أيضًا استخدام <strong>وسيلة عازلة لمنع الحمل</strong> ) مثل الواقي الذكري). اسألي طبيبك للحصول على المشورة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية&nbsp; </strong></p><p dir="RTL">إذا كنت&nbsp; <strong>حاملاً، تظنين أنك حاملا ً</strong> أو <strong>تخططين لإنجاب طفل</strong>، <strong>فلا تأخذي أوجمنتين</strong>&nbsp; دون مراجعة طبيبك. سينظر <strong>طبيبك</strong> في الفائدة التي تعود&nbsp; عليك&nbsp; والمخاطر التي يتعرض لها&nbsp; طفلك جراء تناول أوجمنتين أثناء الحمل.</p><p dir="RTL">يمكنك عادة الإرضاع طبيعيًا&nbsp; أثناء تناولك أوجمنتين. إذا كن ت&nbsp; ترضعين طفلك طبيعيًا أو&nbsp; تفكرين في الرضاعة الطبيعية، <strong>فاستشيري طبيبك قبل تناول أوجمنتين. </strong>&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أوجمنتين يحتوي على أسبارتام&nbsp;&nbsp; </strong></p><p dir="RTL">يحتوي أوجمنتين على <strong>أسبارتام ،</strong> وهو مصدر للفينيل ألانين. إذا كنت لا تتحمل الأسبارتام أو لديك&nbsp; حالة تسمى وجود الفينول كيتون في البول<strong> </strong></p><p dir="RTL">&nbsp;: <strong>(PKU)</strong></p><p dir="RTL">&ccedil;&nbsp;&nbsp; استشر طبيبك لمعرفة ما إذا كان أوجمنتين مناسبًا لك.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>احرص دائمًا على تناول أوجمنتين تمامًا كما أخبرك طبيبك أو الصيدلي.</strong> إذا لم تكن متأكدًاً من كيفية التناول، يرجى مراجعة طبيبك أو الصيدلي.&nbsp;</p><p dir="RTL"><strong>ما هي الكمية التي يجب تناولها&nbsp; </strong></p><p dir="RTL">يقرر طبيبك الجرعة المناسبة لك <strong>مرضى الكلى أو الكبد&nbsp; </strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشاكل بالكلى ، فقد يعطيك طبيبك تركيز مختلف أو دواء مختلف.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشاكل بالكبد، يلزم إجراء المزيد من تحاليل الدم لمعرفة حالة الكبد.</p><p dir="RTL"><strong>كيفية التناول&nbsp; </strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناول أوجمنتين في بداية الوجبة أو قبلها بقليل.&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تتوفر التعليمات الخاصة بكيفية تحضير معلق أوجمنتين في نهاية هذه النشرة الطبية.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رج الزجاجة جيدًاً قبل تناول كل جرعة.&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تزُوَّد العبوة بحقنة أو ملعقة أو كوب لقياس الجرعات، والتي يمكنك استخدامها لقياس الجرعة بدقة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب استخدام حقنة قياس الجرعات لإعطاء الجرعة الصحيحة للأطفال دون سن 3 أشهر. تتوفر التعليمات الخاصة بكيفية استخدام حقنة قياس الجرعات في نهاية هذه النشرة الطبية.</p><p dir="RTL">لا تتناول أوجمنتين لأكثر من 14 يومًا. إذا كنت لا تزال تشعر بأنك لست على ما يرام، يجب عليك <strong>رؤية طبيبك</strong> مرة أخرى.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حال نسيان تناول أوجمنتين&nbsp; </strong></p><p dir="RTL"><strong>لا تتناول جرعة مضاعفة لتعويض الجرعة التي أغفلتها،</strong> فقط تناولها بمجرد تذكرك.&nbsp;</p><p dir="RTL"><strong>إذا لم تكن متأكدًا مما يجب عليك فعله</strong>، فاسأل طبيبك أو الصيدلي.</p><p dir="RTL"><strong>في حال تناول كمية أكثر مما يجب من أوجمنتين&nbsp; </strong></p><p dir="RTL">إذا تناولت كمية أكثر مما&nbsp; يجب من أوجمنتين عن طريق الخطأ ، فمن غير المرجح حدوث أي مشاكل خطيرة. الآثار الجانبية الأكثر شيوعًا لتناول كمية أكثر مما يجب من أوجمنتين هي الغثيان والقيء والإسهال. إذا كنت قلقاً أو تشعر بتوعك:</p><p dir="RTL">&ccedil; اسأل طبيبك أو الصيدلي للحصول على مشورة</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لا تتوقف عن تناول أوجمنتين دون استشارة الطبيب&nbsp; </strong></p><p dir="RTL"><strong>من المهم أن تأخذ دورة كاملة من أوجمنتين.</strong> لا تتوقف عن تناول الدواء إلا إذا نصحك طبيبك بذلك، حتى لو كنت تشعر بتحسن. إذا لم تكمل دورة العلاج بالكامل، فقد تعود العدوى مرة أخرى.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">قد يسبب هذا الدواء آثار اً جانبية -مثل جميع الأدوية- ومع ذلك لا يشعر بها جميع الأشخاص.&nbsp;</p><p dir="RTL"><strong>انتبه إلى الأعراض المهمة&nbsp; </strong></p><p dir="RTL"><strong>ردود الفعل التحسسية الشديدة&nbsp; </strong></p><p dir="RTL">هذه نادرة جداً لدى الأشخاص الذين يتناولون أوجمنتين، وتشمل:&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي المثير للحكة )الشرى)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأوعية الدموية )الالتهاب&nbsp; الوعائي) الذي يمكن رؤيته على شكل بقع حمراء أو أرجوانية بارزة على الجلد، ولكن قد يؤثر على أجزاء أخرى من الجسم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمى وآلام المفاصل وتورم الغدد في الرقبة أو الإبط أو الفخذ</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انتفاخ الوجه أو الفم )الوذمة الوعائية)، مما قد يسبب صعوبة في البلع أو التنفس&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الهبوط&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الصدر يمكن أن يكون علامة على رد فعل تحسسي خطير محتمل يسمى متلازمة كونس.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القيء المتكرر )خلال ساعة إلى 4 ساعات من تلقي الدواء أوجمنتين)، آلام في المعدة، نعاس غير طبيعي، إسهال، وانخفاض ضغط الدم، والتي يمكن أن تكون علامة على رد فعل تحسسي خطير يسمى متلازمة التهاب الأمعاء والقولون الناجم عن الأدوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&ccedil; <strong>احصل على المساعدة الطبية فوراً</strong> إذا ظهرت عليك أي من هذه الأعراض .<strong>توقف عن تناول أوجمنتين.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التفاعلات الجلدية الخطيرة&nbsp; </strong></p><p dir="RTL">هذه نادرة لدى الأشخاص الذين يتناولون أوجمنتين، وتشمل:&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي الذي قد يتحول إلى قرح، ويبدو كبقع صغيرة) بقع مركزية داكنة محاطة بمنطقة شاحبة مع حلقات داكنة حول الحافة - حمامي متعددة الأشكال)&nbsp;</p><p dir="RTL">هذه نادرة جدًاً لدى الأشخاص الذين يتناولون أوجمنتين، وتشمل:&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي منتشر مع ظهور بثور وتقشر الجلد، خاصة حول الفم والأنف والعينين والأعضاء التناسلية )متلازمة ستيفنز- جونسون)،&nbsp; والشكل الأكثر حدة يسبب بثور اً وتقشراً&nbsp; للجلد على معظم سطح الجسم )انحلال البشرة السمي)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي أحمر منتشر مع ظهور بثور صغيرة بها صديد) البثور&nbsp; ذو الطفح الجلدي الظاهر)&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي أحمر متقشر مثير للحكة مع ظهور رضوض تحت الجلد وبثور )التهاب الجلد التقشري الفقاعي)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعراض&nbsp; شبيهة&nbsp; بالإنفلونزا&nbsp; مع&nbsp; الطفح&nbsp; الجلدي،&nbsp; والحمى،&nbsp; وتضخم الغدد،&nbsp; ونتائج&nbsp; غير&nbsp; طبيعية&nbsp; لتحاليل&nbsp; الدم&nbsp; )بما&nbsp; في&nbsp; ذلك&nbsp; خلايا&nbsp; الدم البيضاء فرط الحمضات) &nbsp;وإنزيمات الكبد) ) تفاعل الدواء مع فرط الحمضات والأعراض الجهازية).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يظهر عادة طفح جلدي أحمر على الأرداف كلتيهما، والجزء العلوي الداخلى من الفخذين، وتحت الإبطين، والرقبة ( الطفح الجلدي وبين الثنايا المتماثل والمتعلق بالدواء(SDRIFE)).</p><p dir="RTL">&nbsp;</p><p dir="RTL">&ccedil;&nbsp;&nbsp; <strong>احصل على المساعدة الطب</strong> <strong>ية فوراً</strong> إذا ظهرت عليك أي من هذه الأعراض .<strong>توقف عن تناول أوجمنتين.</strong></p><p dir="RTL"><strong>مشاكل خطيرة بالكبد&nbsp; </strong></p><p dir="RTL">في حالات نادرة، يمكن أن تسبب&nbsp; الأدوية مثل أوجمنتين مشاكل بالكبد، مما يؤدي إلى اصفرار الجلد و/ أو بياض العين.&nbsp;</p><p dir="RTL">&ccedil;&nbsp;&nbsp; اتصل بطبيبك في أقرب وقت إذا ظهرت عليك أي من هذه الأعراض.</p><p dir="RTL"><strong>الإسهال الشديد </strong><strong>)</strong><strong>التهاب القولون&nbsp; الغشائي الكاذب</strong><strong>)&nbsp; </strong></p><p dir="RTL">في حالات نادرة، يمكن أن تسبب الأدوية مثل أوجمنتين التهاب&nbsp; القولون )الأمعاء الغليظة) الذي يسبب الإسهال ويكون عادة مصحوب بالدم والمخاط وآلام في المعدة والحمى.</p><p dir="RTL">&ccedil;&nbsp;&nbsp; اتصل بطبيبك في أقرب وقت إذا ظهرت عليك أي من هذه الأعراض.</p><p dir="RTL"><strong>الآثار الجانبية الشائعة جداً&nbsp; </strong></p><p dir="RTL">من بين كل <strong>10</strong> أشخاص، قد تظهر هذه الأعراض لدى<strong> أكثر من </strong>شخص:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال )عند البالغين).</p><p dir="RTL"><strong>الآثار الجانبية الشائعة&nbsp; </strong></p><p dir="RTL">من بين كل <strong>10</strong> أشخاص، قد تظهر هذه الأعراض لدى شخص<strong> واحد</strong>:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القلاع )عدوى فطرية تسببها المبيضة وتصيب المهبل أو الفم أو ثنايا الجلد)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالغثيان )الدوار)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القيء</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال )عند الأطفال)&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية غير الشائعة&nbsp; </strong></p><p dir="RTL">من بين كل <strong>100</strong> شخص، قد تظهر هذه الأعراض لدى شخص<strong> واحد</strong>:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوخة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عسر الهضم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحكة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي البارز المثير للحكة )الشرى )</p><p dir="RTL">الآثار الجانبية غير الشائعة التي قد تظهر في تحاليل الدم :</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في بعض المواد )الإنزيمات) التي ينتجها الكبد&nbsp; <strong>الآثار الجانبية النادرة&nbsp; </strong></p><p dir="RTL">من بين كل <strong>1000</strong> شخص، قد تظهر هذه الأعراض لدى شخص<strong> واحد</strong>:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي الذي قد يتحول إلى قرح، ويبدو كبقع صغيرة ) بقع مركزية داكنة محاطة بمنطقة شاحبة مع حلقات داكنة حول الحافة - حمامي متعددة الأشكال) )انظر &quot;التفاعلات الجلدية الخطيرة&quot; سابقًا في القسم 4)</p><p dir="RTL">الآثار الجانبية النادرة التي قد تظهر في تحاليل الدم :</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد خلايا الدم البيضاء )قلة الكريات البيضاء، بما في ذلك قلة العدلات)&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد الخلايا التي تساعد على تجلط الدم )قلة الصفيحات)</p><p dir="RTL"><strong>الآثار الجانبية النادرة جداً&nbsp; </strong></p><p dir="RTL">من بين كل <strong>10,000</strong><strong> </strong>شخص، قد تظهر هذه الأعراض لدى شخص<strong> واحد</strong>:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ردود الفعل التحسسية الشديدة )انظر أيضا &quot;<strong>ردود الفعل التحسسية الشديدة</strong>&quot; سابقا في القسم 4)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التفاعلات الجلدية الخطيرة )انظر أيضا <strong>&quot;التفاعلات الجلدية الخطيرة</strong>&quot; سابقا في القسم 4)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الكبد )التهاب الكبد الوبائي) )انظر أيضا &quot;<strong>المشاكل الخطيرة بالكبد</strong>&quot; سابقا في القسم 4)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اصفرار بياض العين أو الجلد )اليرقان) )انظر أيضا &quot;<strong>المشاكل الخطيرة بالكبد</strong>&quot; سابقا في القسم 4)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأمعاء الغليظة )انظر أيضا &quot;<strong>الإسهال الحاد</strong>&quot; سابقا في القسم 4)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الكلية)الالتهاب الكلوي)&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الوقت الذي يستغرقه الدم للتجلط</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النشاط غير المعتاد )فرط النشاط)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النوبات )التشنجات)&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اللسان الأسود الذي يبدو مشعرًا</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الغشاء الواقي المحيط بالدماغ )التهاب السحايا العقيم)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي مع ظهور بثور مرتبة بشكل دائري مع تقشر مركزي أو مثل سلسلة من اللآلئ )داء الجلوبولين المناعيأ الخطي).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأسنان الصفراء التي يمكن تنظيفها عادة بالفرشاة&nbsp;</p><p dir="RTL">&nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية النادرة جدًا التي قد تظهر في تحاليل الدم أو البول:&nbsp; </strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض حاد في عدد خلايا الدم البيضاء )ندرة المحببات)&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تدمير خلايا الدم الحمراء بسرع ة كبيرة )فقر الدم الانحلالي)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بلورات في البول</p><p dir="RTL">&ccedil; <strong>تحدث إلى طبيبك أو الصيدلي</strong> إذا أصبحت أي من الآثار الجانبية المذكورة <strong>شديدة أو مزعجة</strong>، إو إذ ا لاحظت أي آثار جانبية غير مدرجة في هذه النشرة الطبية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحفظ هذا الدواء بعيدًاً عن رؤية ومتناول الأطفال.</p><p dir="RTL">لا تتناول أوجمنتين بعد تاريخ انتهاء الصلاحية المدون على العبوة.</p><p dir="RTL">يحُفظ هذا الدواء في العلبة الأصلية في مكان جاف لحمايته من الرطوبة في درجة حرارة أقل من 25&deg;م.&nbsp;</p><p dir="RTL">بمجرد تحضير المعلق، يجب تخزين المعلق في الثلاجة)<sup> </sup>2<sup>◦</sup> م إل ى 8<sup>◦</sup> م) .</p><p dir="RTL">يجب عدم التجميد.</p><p dir="RTL">تخلص من أي معلق غير مستخدم بعد 7 أيام من فتح الزجاجة لأول مرة.</p><p dir="RTL">لا تتخلص من الأدوية عن طريق إلقائها في مياه الصرف أو مع المخلفات المنزلية. استشر الصيدلي الخاص بك عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. ستساعد هذه الإجراءات على حماية البيئة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL"><strong>على ماذا يحتوي معلق أوجمنتين </strong><strong>228</strong><strong>ملجم و</strong><strong>457</strong><strong>ملجم&nbsp; </strong></p><p dir="RTL">الأموكسيسيلين وحمض الكلاڨيولانيك هما المواد الفعالة في هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي كل </strong><strong>5</strong><strong> مل من المعلق المُذاب على أي مما يلي:&nbsp; </strong></p><p dir="RTL">أموكسيسيلين ثلاثي الهيدرات بما&nbsp; يعادل 200 ملجم من الأموكسيسيلين، وبوتاسيوم كلاڨيولانيت بما يعادل 62.5 ملجم من حمض الكلاڨيولانيك أموكسيسيلين ثلاثي الهيدرات بما&nbsp; يعادل 400 مجم من الأموكسيسيلين، وبوتاسيوم كلاڨيولانيت بما يعادل 57 ملجم من حمض الكلا ڨيولانيك</p><p dir="RTL">&nbsp;<strong>مواد أخرى غير فعالة: </strong>&nbsp;</p><p dir="RTL">صمغ الزانثان، هيدروكسي پروپيل ميثيل سليولوز، سيليكا غروية، حمض الساكسينيت، ثاني أوكسيد السيليكون، نكهات التوت والبرتقال1 والبرتقال2 والشراب الذهبي الجاف، أسپارتام.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كيف يبدو أوجمنتين&nbsp; وما هي محتويات العبوة&nbsp; </strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">يتوفر مسحوق أوجمنتين للمعلق الفموي في زجاجات؛ تحتوي كل قارورة زجاجية شفافة على مسحوق أبيض أو شبه أبيض. يحتاج المسحوق إلى تذويبه بالماء قبل تناوله عن طريق الفم. يوفر المسحوق في كل زجاجة إما:&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">200 ملجم من الأموكسيسيلين و 28.5 ملجم من حمض الكلافولانيك لكل 5 مل أو 400 ملجم من الأموكسيسيلين و57 ملجم من حمض الكلافولانيك لكل 5 مل عند تذويبه على النحو الموصي به.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">المسحوق المذاب للمعلق الفموي لونه شبه أبيض وبنكهة مزيج الفواكه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p>&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;التعليمات المفصلة/ معلومات لمتخصصي الرعاية الصحية </strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">تأكد من سلامة الغطاء المحكم للقارورة بغطاء ألومنيوم قبل الاستخدام. في حالة القارورات بغطاء بلاستيكي مقاوم لاستخدام الطفل، تأكد من سلامة القارورة المدعومة برقاقة معدنية قبل الاستخدام.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">عند الاستخدام، المسحوق الجاف يجب أن يتم تذويبه ليتكون محلول معلق يتم يتناوله عن طريق الفم&nbsp; بالطريقة الآتية:</p><p dir="RTL">1.&nbsp;&nbsp;&nbsp;&nbsp; اقلب الزجاجة ورجها لتحريك المسحوق.</p><p dir="RTL">2.&nbsp;&nbsp;&nbsp;&nbsp; أضف مقدار الماء )على النحو المبين أدناه). اقلب الزجاجة ورجها جيداً.</p><p dir="RTL">3.&nbsp;&nbsp;&nbsp;&nbsp; يمكن إتباع طريقة أخرى، املأ الزجاجة بالماء حتى أسفل العلامة الموجودة على ملصق الزجاجة.&nbsp;</p><p dir="RTL">اقلب الزجاجة ورجها جيداً، ثم أكمل بالماء حتى العلامة. اقلب الزجاجة ورجها مرة أخرى.</p><p dir="RTL">4.&nbsp;&nbsp;&nbsp;&nbsp; اترك الزجاجة في وضع قائم لمدة 5 دقائق لضمان انتشار المسحوق بالكامل في الماء.</p><p dir="RTL">5.&nbsp;&nbsp;&nbsp;&nbsp; رج الزجاجة جيداً قبل تناول كل جرعة.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:557px"><tbody><tr><td colspan="3" style="vertical-align:top"><p dir="RTL">معلق أوجمنتين 228 ملجم / 5 مل</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">الحجم النهائي للمعلق بعد التحضير)مل)</p></td><td style="vertical-align:top"><p dir="RTL">حجم الماء المطلوب إضافته للتحضير)مل)&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">الوزن المعبأ) جرام)</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;70</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp; 64</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;7.7</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;140</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;128</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp; 15.4</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:557px"><tbody><tr><td colspan="3" style="vertical-align:top"><p dir="RTL">معلق أوجمنتين 457 ملجم / 5 مل</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">الحجم النهائي للمعلق بعد التحضير )مل)</p></td><td style="vertical-align:top"><p dir="RTL">حجم الماء المطلوب إضافته للتحضير )مل)&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">الوزن المعبأ)جرام)</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp; 35</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;31</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp; 6.3</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;70</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;62</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp; 12.6</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;140</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp; 124</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;25.2</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL">قد يكون معلق أوجمنتين 228 ملجم / 5 مل و 457 ملجم/&nbsp; 5 مل مزود بأداة لقياس الجرعة</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL">لا تتوفر جميع أشكال العبوات في كل بلد.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;أوجمنتين</strong> علامة تجارية مملوكة أو مرخصة<strong> </strong>لمجموعة شركات جلاكسو سميث كلاين.</p><p dir="RTL">&copy; 2023 مجموعة شركات جلاكسو سميث كلاين، جميع الحقوق محفوظة .</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>تصنيع:&nbsp; </strong></p><p dir="RTL">جلاكسو ويلكام بروداكشن*، مايين، فرنسا.</p><p dir="RTL"><strong>تعبئة:&nbsp; </strong></p><p dir="RTL">جلاكسو العربية السعودية المحدودة* جدة، المملكة العربية السعودية .</p><p dir="RTL"><strong>تسويق :</strong></p><p dir="RTL">جلاكسو العربية السعودية المحدودة* جدة، المملكة العربية السعودية.</p><p dir="RTL">*عضو في مجموعة شركات جلاكسو سميث كلاين.</p><p dir="RTL">&nbsp;</p><p>&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>للإستفسار عن أي معلومات عن هذا المستحضر الدوائي، يرجى الإتصال بالأرقام التالية:</strong></p><p dir="RTL">جلاكسو سميث كلاين &ndash; المكتب الرئيسي، جدة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هاتف: 6536666 )12( 966 +</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جوال:9882-904-56 966 +</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني: gcc.medinfo@gsk.com</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: https://gskpro.com/en-sa/</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ص.ب. 55850، جدة 21544، المملكة العربية السعودية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><!--[if gte vml 1]><v:roundrect
 id="Rectangle_x003a__x0020_Rounded_x0020_Corners_x0020_1" o:spid="_x0000_s1028"
 style='position:absolute;left:0;text-align:left;margin-left:38pt;margin-top:6.3pt;
 width:469pt;height:217pt;z-index:251663360;visibility:visible;
 mso-wrap-style:square;mso-width-percent:0;mso-height-percent:0;
 mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:margin;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:margin;mso-height-relative:margin;v-text-anchor:middle'
 arcsize="10923f" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" strokecolor="black [3213]" strokeweight="2.25pt">
 <v:stroke joinstyle="miter"/>
 <w:wrap anchorx="margin"/>
</v:roundrect><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL">&nbsp;</p><p>&nbsp;</p><p dir="RTL">&nbsp;<strong>للإبلاغ عن أي آثار جانبية</strong></p><p dir="RTL"><strong><em>المملكة العربية السعودية</em></strong></p><p dir="RTL"><strong>- المركز الوطني للتيقظ والسلامة الدوائية </strong><strong>NPC</strong><strong>)</strong><strong>)</strong></p><ul><li><ul><li dir="RTL">الاتصال بالرقم الموحد: 19999</li><li dir="RTL">البريد الإلكتروني<u>: </u>npc.drug@sfda.gov.sa</li><li dir="RTL">الموقع الإلكتروني:<u> </u>https://ade.sfda.gov.sa</li></ul></li></ul><p dir="RTL"><strong>- جلاكسو سميث كلاين &ndash; المكتب الرئيسي، جدة.</strong></p><ul><li><ul><li dir="RTL">هاتف: 6536666 )12(966 +</li><li dir="RTL">جوال:9882-904-56 966 +</li><li dir="RTL">البريد الإلكتروني: saudi.safety@gsk.com</li><li dir="RTL">الموقع الإلكتروني:<u> </u>https://gskpro.com/en-sa/<u> </u></li></ul></li></ul><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ص.ب. 55850، جدة 21544، المملكة العربية السعودية.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إن هذا الدواء </strong></p><p dir="RTL">-&nbsp; الدواء مستحضر يؤثر على صحتك ، واستهلاكه خلافا للتعليمات يعرضك للخطر.&nbsp;</p><p dir="RTL">-&nbsp; اتبع بدقة وصفة الطبيب، وطريقة الاستعمال المنصوص عليه ا، وتعليمات الصيدلانى الذى صرفها لك.&nbsp;</p><p dir="RTL">-&nbsp; فالطبيب والصيدلانى هما الخبيران بالدواء ، وبنفعه وضرره.&nbsp;</p><p dir="RTL">-&nbsp; لا تقطع مدة العلاج المحددة لك من تلقاء نفسك.&nbsp;</p><p dir="RTL">-&nbsp; لا تكرر صرف الدواء بدون استشارة الطبيب .</p><p dir="RTL">-&nbsp; احتفظ بجميع الأدوية بعيداً عن متناول لأطفال.&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; مجلس وزراء الصحة العرب&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;اتحاد الصيادلة العرب</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            إصدار رقم: GDS29
تاريخ الإصدار: 7 سبتمبر 2023


        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Augmentin Suspension
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                AUGMENTIN suspension 228 mg/5 mL: When reconstituted each 5 mL contains 200 mg amoxicillin (as amoxicillin trihydrate) and 28.5 mg clavulanic acid (as potassium clavulanate).


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                A white to off-white dry powder for reconstitution in water to form an off-white mixed-fruit flavoured suspension.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>AUGMENTIN </em>should be used in accordance with local official antibiotic-prescribing guidelines and local susceptibility data.</p><p><em>AUGMENTIN</em><strong> </strong>suspension (228 mg/5 mL and 457mg/5 mL), for twice daily oral dosing, is indicated for short term treatment of bacterial infections at the following sites when amoxicillin resistant beta-lactamase producing strains are suspected as the cause. In other situations, amoxicillin alone should be considered.</p><p><em>Upper respiratory tract infections (including ENT)</em> e.g. recurrent tonsillitis, sinusitis, otitis media.</p><p><em>Lower respiratory tract infections </em>e.g. acute exacerbations of chronic bronchitis, lobar and bronchopneumonia.</p><p><em>Urinary tract infections</em> e.g. cystitis, urethritis, pyelonephritis</p><p><em>Skin and soft </em>t<em>issue infections</em> e.g. cellulitis, animal bites.</p><p><em>Dental infections</em> e.g. severe dental abscess with spreading cellulitis.</p><p>Susceptibility to <em>AUGMENTIN</em> will vary with geography and time (see <em>Pharmacological Properties, Pharmacodynamics</em> for further information). Local susceptibility data should be consulted where available, and microbiological sampling and susceptibility testing performed where necessary.</p><p>Mixed infections caused by amoxicillin-susceptible organisms in conjunction with</p><p><em>AUGMENTIN</em><strong> </strong>susceptible beta-lactamase-producing organisms may be treated with <em>AUGMENTIN</em><strong> </strong>suspension 228 mg/5mL and 457 mg/5 mL. These infections should not require the addition of another antibiotic resistant to beta-lactamases.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Dosage depends on the age, weight and renal function of the patient and the severity of the infection.</p><p>Dosages are expressed throughout in terms of amoxicillin/clavulanate content except when doses are stated in terms of an individual component.</p><p>To minimise potential gastrointestinal intolerance, administer at the start of a meal. The absorption of AUGMENTIN is optimised when taken at the start of a meal.&nbsp;</p><p>Treatment should not exceed 14 days without review.</p><p><!--[if gte vml 1]><o:wrapblock><v:group
  id="Group_x0020_20283" o:spid="_x0000_s2050" style='position:absolute;left:0;
  text-align:left;margin-left:88.6pt;margin-top:71.5pt;width:434.85pt;height:.7pt;
  z-index:251659264;mso-position-horizontal-relative:page;
  mso-position-vertical-relative:page' coordsize="55223,91" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
  <v:shape id="Shape_x0020_25160" o:spid="_x0000_s2051" style='position:absolute;
   width:55223;height:91;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="5522341,9144" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m,l5522341,r,9144l,9144,,e" fillcolor="black" stroked="f"
   strokeweight="0">
   <v:stroke miterlimit="83231f" joinstyle="miter"/>
   <v:path arrowok="t" textboxrect="0,0,5522341,9144"/>
  </v:shape><w:wrap type="topAndBottom" anchorx="page" anchory="page"/>
 </v:group><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="580" height="1" src="file:///C:/Users/aa630244/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--><br />Therapy can be started parenterally and continued with an oral preparation.</p><p>&nbsp;</p><p>AUGMENTIN bottle presentations for suspension may be supplied with a plastic dosing device. For preparation of the suspensions see Instructions for Use/Handling.</p><p>The usual recommended daily dosage is:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; Lower dose: 25/3.6 to 45/6.4<strong><em> </em></strong>mg/kg/day in two divided doses for mild to moderate infections (upper respiratory tract infections e.g. recurrent tonsillitis, lower respiratory infections and skin and soft tissue infections).</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp; Higher dose: 45/6.4 to 70/10 mg/kg/day in two divided doses for the treatment of more serious infections (upper respiratory tract infections e.g. otitis media and sinusitis, lower respiratory tract infections e.g. bronchopneumonia and urinary tract infections).</p><p>No clinical data are available on doses above 45/6.4 mg/kg/day in children under 2 years.</p><p>There are no clinical data for AUGMENTIN suspension 228 mg/5 mL and 457 mg/5 mL to make dosage recommendations for children under 2 months old.&nbsp;</p><p>The tables below give dosage guidance for children.</p><p><em>Children 2 years and over</em><!--[if supportFields]><i style='mso-bidi-font-style:
normal'><span style='font-weight:normal'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_6137b95a-56e2-437a-9c7d-e60d56eff0c9 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></i><![endif]--><em>&nbsp;</em><!--[if supportFields]><i
style='mso-bidi-font-style:normal'><span style='font-weight:normal'><span
style='mso-element:field-end'></span></span></i><![endif]--></p><table border="0" cellspacing="0" cellpadding="0" style="width:577px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong><em>AUGMENTIN suspension 228 mg/5 mL&nbsp; </em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Body weight (kg)</p></td><td style="vertical-align:top"><p>For lower dose range (mL every 12 hours)</p></td><td style="vertical-align:top"><p>For higher dose range (mL every 12 hours)</p></td></tr><tr><td style="vertical-align:top"><p>12 to 16</p><p>17 to 26</p></td><td style="vertical-align:top"><p>5</p><p>10</p></td><td style="vertical-align:top"><p>10</p><p>15</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:577px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong><em>AUGMENTIN suspension 457 mg/5 mL&nbsp; </em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Body weight (kg)</p></td><td style="vertical-align:top"><p>For lower dose range (mL every 12 hours)</p></td><td style="vertical-align:top"><p>For higher dose range (mL every 12 hours)</p></td></tr><tr><td><p>&nbsp;12 to 16</p><p>17 to 26</p><p>27 to 35</p><p>36 to &lt; 40</p></td><td><p>2.5</p><p>5</p><p>7.5</p><p>10</p></td><td><p>5</p><p>7.5</p><p>10</p><p>12.5</p></td></tr></tbody></table><p><em>&nbsp;</em></p><p><em>Children aged 2 months to under 2 years</em><!--[if supportFields]><b style='mso-bidi-font-weight:normal'><i
style='mso-bidi-font-style:normal'><span style='mso-element:field-begin'></span></i></b><i
style='mso-bidi-font-style:normal'> DOCVARIABLE
vault_nd_32798ebf-8c5d-44b6-a68b-5fafeb6d629e \* MERGEFORMAT <b
style='mso-bidi-font-weight:normal'><span style='mso-element:field-separator'></span></b></i><![endif]--><em>&nbsp;</em><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><i style='mso-bidi-font-style:normal'><span
style='mso-element:field-end'></span></i></b><![endif]--></p><p>&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:515px"><tbody><tr><td colspan="2"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="4" style="vertical-align:top"><p><strong><em>&nbsp;&nbsp;AUGMENTIN</em></strong> suspension <strong>457 mg/5 mL </strong></p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p><strong>Body Weight (kg) </strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Lower dose at </strong></p><p><strong>25/3.6 mg/kg/day (mL every </strong></p><p><strong>12 hours) </strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Higher dose at 45/6.4 mg/kg/day (mL every 12 hours) </strong></p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="2"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>2</p><p>3</p><p>4</p><p>5</p><p>6</p><p>7</p><p>8</p><p>9</p></td><td colspan="2" style="vertical-align:top"><p>0.3</p><p>0.5</p><p>0.6</p><p>0.8</p><p>0.9</p><p>1.1</p><p>1.3</p><p>1.4</p></td><td colspan="2" style="vertical-align:top"><p>0.6</p><p>0.8</p><p>1.1</p><p>1.4</p><p>1.7</p><p>2.0</p><p>2.3</p><p>2.5</p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="4" style="vertical-align:top"><p><strong><em>&nbsp; AUGMENTIN</em></strong> suspension <strong>457 mg/5 mL </strong></p></td><td colspan="2" rowspan="3" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Body Weight (kg) </strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Lower dose at </strong></p><p><strong>25/3.6 mg/kg/day (mL every </strong></p><p><strong>12 hours) </strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Higher dose at 45/6.4 mg/kg/day (mL every 12 hours) </strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>10</p><p>11</p><p>12</p><p>13</p><p>14</p><p>15</p></td><td colspan="2" style="vertical-align:top"><p>1.6</p><p>1.7</p><p>1.9</p><p>2.0</p><p>2.2</p><p>2.3</p></td><td colspan="2" style="vertical-align:top"><p>2.8</p><p>3.1</p><p>3.4</p><p>3.7</p><p>3.9</p><p>4.2</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p><em>Renal Impairment</em><!--[if supportFields]><i style='mso-bidi-font-style:normal'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_f91e8b4b-319b-4561-8084-154e0387502d \* MERGEFORMAT <span
style='mso-element:field-separator'></span></i><![endif]--><em>&nbsp;</em><!--[if supportFields]><i
style='mso-bidi-font-style:normal'><span style='mso-element:field-end'></span></i><![endif]--></p><p>No adjustment in dose is required in patients with creatinine clearance greater than 30 mL/min.&nbsp;</p><p><em>AUGMENTIN</em> suspension 228 mg/5 mL and 457 mg/5 mL are not recommended in patients with a creatinine clearance of less than 30 mL/min.</p><p><em>Hepatic Impairment</em><!--[if supportFields]><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_6ef4caaf-e3e7-4cb4-8eda-6dcc4eb8916f \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p>Administer with caution; monitor hepatic function at regular intervals.&nbsp; There are insufficient data on which to base a dosage recommendation.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                AUGMENTIN is contra-indicated  
-	in patients with a history of hypersensitivity to beta-lactams, e.g. penicillins and cephalosporins. 
 
-	in patients with a previous history of AUGMENTIN-associated jaundice/hepatic dysfunction

 
-	in patients with a previous history of AUGMENTIN-associated jaundice/hepatic dysfunction. 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Before initiating therapy with <em>AUGMENTIN</em>, careful enquiry should be made concerning previous hypersensitivity reactions to penicillins, cephalosporins or other allergens.</p><p>Serious and occasionally fatal hypersensitivity reactions (including anaphylactoid and severe cutaneous adverse reactions) have been reported in patients on penicillin therapy.&nbsp; These reactions are more likely to occur in individuals with a history of penicillin hypersensitivity (see <em>Contraindications</em>). Hypersensitivity reactions can also progress to Kounis syndrome, a serious allergic reaction that can result in myocardial infarction. Presenting symptoms of such reactions can include chest pain occurring in association with an allergic reaction to <em>AUGMENTIN</em> (see <em>Undesirable Effects</em>). Drug-induced enterocolitis syndrome has been reported mainly in children receiving <em>AUGMENTIN</em> (see <em>Undesirable Effects</em>). Drug-induced enterocolitis syndrome is an allergic reaction with the leading symptom of protracted vomiting (1-4 hours after medicinal product administration) in the absence of allergic skin or respiratory symptoms. Further symptoms could comprise abdominal pain, lethargy, diarrhoea, hypotension or leucocytosis with neutrophilia. In severe cases, drug-induced enterocolitis syndrome can progress to shock. If an allergic reaction occurs, AUGMENTIN therapy must be discontinued and appropriate alternative therapy instituted. Serious anaphylactic reactions require immediate emergency treatment with adrenaline. Oxygen, intravenous (i.v.) steroids and airway management (including intubation) may also be required.&nbsp;</p><p><em>AUGMENTIN</em> should be avoided if infectious mononucleosis is suspected since the occurrence of a morbilliform rash has been associated with this condition following the use of amoxicillin.</p><p>Prolonged use may also occasionally result in overgrowth of non-susceptible organisms.</p><p>Pseudomembranous colitis has been reported with the use of antibiotics and may range in severity from mild to life-threatening. Therefore, it is important to consider its diagnosis in patients who develop diarrhoea during or after antibiotic use. If prolonged or significant diarrhoea occurs or the patient experiences abdominal cramps, treatment should be discontinued immediately and the patient investigated further.</p><p>&nbsp;</p><p>Abnormal prolongation of prothrombin time (increased INR) has been reported rarely in patients receiving <em>AUGMENTIN</em> and oral anticoagulants.&nbsp; Appropriate monitoring should be undertaken when anticoagulants are prescribed concurrently.&nbsp; Adjustments in the dose of oral anticoagulants may be necessary to maintain the desired level of anticoagulation.</p><p>Changes in liver function tests have been observed in some patients receiving <em>AUGMENTIN</em>. The clinical significance of these changes is uncertain but <em>AUGMENTIN</em> should be used with caution in patients with evidence of hepatic dysfunction.</p><p>&nbsp;</p><p>Cholestatic jaundice, which may be severe, but is usually reversible, has been reported rarely. Signs and symptoms may not become apparent for up to six weeks after treatment has ceased.</p><p>In patients with renal impairment <em>AUGMENTIN</em> suspension 228 mg/5 mL and 457 mg/5 mL are not recommended.</p><p>In patients with reduced urine output, crystalluria has been observed very rarely, predominantly with parenteral therapy.&nbsp; During the administration of high doses of amoxicillin, it is advisable to maintain adequate fluid intake and urinary output in order to reduce the possibility of amoxicillin crystalluria <em>(</em>see<em> Overdose). </em></p><p>&nbsp;</p><p><em>AUGMENTIN</em> 228 mg/5 mL and 457 mg/5mL suspensions contain aspartame, which is a source of phenylalanine and so should be used with caution in patients with phenylketonuria.<strong> </strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Concomitant use of probenecid is not recommended. Probenecid decreases the renal tubular secretion of amoxicillin. Concomitant use with <em>AUGMENTIN</em> may result in increased and prolonged blood levels of amoxicillin but not of&nbsp; clavulanic acid.</p><p>Concomitant use of allopurinol during treatment with amoxicillin can increase the likelihood of allergic skin reactions. There are no data on the concomitant use of <em>AUGMENTIN</em><strong> </strong>and allopurinol.</p><p>In common with other antibiotics<em>, AUGMENTIN</em> may affect the gut flora, leading to lower oestrogen reabsorption and reduced efficacy of combined oral contraceptives.</p><p>In the literature there are rare cases of increased international normalised ratio in patients maintained on acenocoumarol or warfarin and prescribed a course of amoxicillin.&nbsp; If coadministration is necessary, the prothrombin time or international normalised ratio should be carefully monitored with the addition or withdrawal of <em>AUGMENTIN</em>.</p><p>In patients receiving mycophenolate mofetil, reduction in pre-dose concentration of the active metabolite mycophenolic acid of approximately 50% has been reported following commencement of oral amoxicillin plus clavulanic acid. The change in pre-dose level may not accurately represent changes in overall MPA exposure.</p><p>Penicillins may reduce the excretion of methotrexate causing a potential increase in toxicity.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy <!--[if supportFields]><span style='mso-element:field-begin'></span><span
style='mso-spacerun:yes'> </span>DOCVARIABLE
vault_nd_c2650f60-8394-4cd6-87c6-179ecc98ce57 \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p>Pregnancy Category B: Reproduction studies in animals (mice and rats at doses up to 10 times the human dose) with orally and parenterally administered <em>AUGMENTIN</em> have shown no teratogenic effects.&nbsp; In a single study in women with pre-term, premature rupture of the foetal membrane (pPROM), it was reported that prophylactic treatment with <em>AUGMENTIN</em> may be associated with an increased risk of necrotising enterocolitis in neonates. As with all medicines, use should be avoided in pregnancy, unless considered essential by the physician.</p><p>&nbsp;</p><p>Lactation<em> </em><!--[if supportFields]><i style='mso-bidi-font-style:normal'><span
style='font-weight:normal'><span style='mso-element:field-begin'></span><span
style='mso-spacerun:yes'> </span>DOCVARIABLE
vault_nd_6158bef0-9ae0-43ec-a13b-650828346a0c \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></i><![endif]--><em>&nbsp;</em><!--[if supportFields]><i
style='mso-bidi-font-style:normal'><span style='font-weight:normal'><span
style='mso-element:field-end'></span></span></i><![endif]--></p><p><em>AUGMENTIN</em> may be administered during the period of lactation.&nbsp; With the exception of the risk of sensitisation, associated with the excretion of trace quantities in breast milk, there are no known detrimental effects for the breast-fed infant.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adverse effects on the ability to drive or operate machinery have not been observed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>4.8.1</strong> <strong>: adverse reactions </strong>&nbsp;</p><p>Data from large clinical trials were used to determine the frequency of very common to rare undesirable effects. The frequencies assigned to all other undesirable effects (i.e., those occurring at &lt;1/10,000) were mainly determined using post-marketing data and refer to a reporting rate rather than a true frequency.&nbsp;</p><p>The following convention has been used for the classification of frequency:</p><p>very common &ge;1/10 common &ge;1/100 to &lt;1/10&nbsp; uncommon &ge;1/1000 to &lt;1/100&nbsp; rare &ge;1/10,000 and &lt;1/1000&nbsp;</p><p>very rare &lt;1/10,000.&nbsp;&nbsp;</p><p><strong>Infections and infestations&nbsp;&nbsp; </strong></p><p>Common&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mucocutaneous candidiasis</p><p>Blood and lymphatic system disorders <!--[if supportFields]><span
style='mso-element:field-begin'></span><span
style='mso-spacerun:yes'> </span>DOCVARIABLE
vault_nd_fce85694-ac8d-4a33-9ad2-32e11c11b7ac \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p>Rare&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reversible leucopenia (including neutropenia) and thrombocytopenia</p><p>Very rare &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reversible agranulocytosis and haemolytic anaemia. Prolongation of bleeding time and prothrombin time</p><p>Immune system disorders <!--[if supportFields]><span
style='mso-element:field-begin'></span><span
style='mso-spacerun:yes'> </span>DOCVARIABLE
vault_nd_59707f65-548e-491a-bc31-287ef3a74930 \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p>Very rare&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Angioneurotic oedema, anaphylaxis (see Special warnings and precautions for use), serum sickness-like syndrome, hypersensitivity vasculitis (see also<em> Skin and subcutaneous tissue disorders</em>).</p><p>Nervous system disorders<!--[if supportFields]><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_1ebe27e2-3c87-4208-a31a-fed0400e012a \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p>Uncommon &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness, headache&nbsp;</p><p>Very rare &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reversible hyperactivity, aseptic meningitis, convulsions. Convulsions may occur in patients with impaired renal function or in those receiving high doses.</p><p>Cardiac disorders<!--[if supportFields]><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_aef528df-56a0-4413-818d-9d5489967dd0 \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p>Very rare &nbsp;&nbsp;&nbsp;&nbsp; Kounis syndrome (see <em>Special warnings and precautions for use</em>).&nbsp;</p><p>&nbsp;</p><p><strong>Gastrointestinal disorders Adults: </strong></p><p>Very common&nbsp;&nbsp; Diarrhoea</p><p>Common&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;Nausea, vomiting <strong>Children: </strong></p><p>Common <strong><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;</em></strong>Diarrhoea, nausea, vomiting</p><p><strong>All populations: </strong></p><p>Nausea is more often associated with higher oral dosages. If gastrointestinal reactions are evident, they may be reduced by taking <em>AUGMENTIN</em> at the start of a meal.</p><p>Uncommon&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Indigestion&nbsp;</p><p>Very rare &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Antibiotic-associated colitis (including pseudomembranous colitis and haemorrhagic colitis, drug-induced enterocolitis syndrome)</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (see Warnings and Precautions). &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Black hairy tongue</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Superficial tooth discolouration has been reported very rarely in children. Good oral hygiene may help to prevent tooth discolouration as it can usually be removed by brushing.</p><p>Hepatobiliary disorders <!--[if supportFields]><span
style='mso-element:field-begin'></span><span
style='mso-spacerun:yes'> </span>DOCVARIABLE
vault_nd_84eea823-2218-43da-b462-94d6930edca9 \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p>Uncommon&nbsp; &nbsp;&nbsp; A moderate rise in AST and/or ALT has been noted in patients treated with beta-lactam class antibiotics, but the significance of these findings is unknown.</p><p>Very Rare &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hepatitis and cholestatic jaundice. These events have been noted with other penicillins and cephalosporins.&nbsp;</p><p>Hepatic events have been reported predominantly in males and elderly patients and may be associated with prolonged treatment. These events have been very rarely reported in children.</p><p><strong><em>&nbsp;</em></strong></p><p>Signs and symptoms usually occur during or shortly after treatment but in some cases may not become apparent until several weeks after treatment has ceased.&nbsp; These are usually reversible. Hepatic events may be severe and in extremely rare circumstances, deaths have been reported. These have almost always occurred in patients with serious underlying disease or taking concomitant medications known to have the potential for hepatic effects.</p><p>&nbsp;</p><p>Skin and subcutaneous tissue disorders <!--[if supportFields]><span
style='mso-element:field-begin'></span><span
style='mso-spacerun:yes'> </span>DOCVARIABLE vault_nd_ff0d1a1d-6c7a-47f6-83e2-f3cc0f802df5
\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p>Uncommon&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; Skin rash, pruritus, urticaria&nbsp;</p><p>Rare &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Erythema multiforme</p><p>Very rare &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stevens-Johnson syndrome, toxic epidermal necrolysis, bullous exfoliative-dermatitis, acute generalised exanthemous pustulosis (AGEP), drug reaction with eosinophilia and systemic symptoms (DRESS), and symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) (baboon syndrome) (see also <em>Immune system disorders</em>).</p><p>If any hypersensitivity dermatitis reaction occurs, treatment should be discontinued.</p><p>Linear IgA disease.</p><p>Renal and urinary disorders <!--[if supportFields]><span
style='mso-element:field-begin'></span><span
style='mso-spacerun:yes'> </span>DOCVARIABLE
vault_nd_b97c20fd-a285-4521-97cc-e19221f818f3 \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p>Very rare &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Interstitial nephritis, crystalluria <em>(</em>see<em> Overdose)</em></p><p><strong>&nbsp;</strong></p><p><strong>To report any side effect(s): </strong></p><p>Kingdom of Saudi Arabia<!--[if supportFields]><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_bb0fc5af-3550-4c00-987e-44c091c58a30 \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p><strong>-National Pharmacovigilance centre (NPC) </strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reporting Hotline: 19999</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa<u> </u></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: <u>https://ade.sfda.gov.sa</u></p><p><strong>-GSK - Head Office, Jeddah </strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tel:&nbsp; +966-12-6536666</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mobile: +966-56-904-9882</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Email: <u>saudi.safety@gsk.com</u>&nbsp;&nbsp;&nbsp;&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: <u>https://gskpro.com/en-sa/</u>&nbsp;&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; P.O Box 55850, Jeddah 21544, Saudi Arabia.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>For any information about this medicinal product, please contact: </strong></p><p><strong>GSK- Head Office, Jeddah</strong><strong> </strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tel:&nbsp; +966-12-6536666</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mobile: +966-56-904-9882</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Email: <u>gcc.medinfo@gsk.com</u></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: <u>https://gskpro.com/en-sa/</u>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; P.O. Box 55850, Jeddah 21544, Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Gastrointestinal symptoms and disturbance of the fluid and electrolyte balances may be evident. Gastrointestinal symptoms may be treated symptomatically with attention to the water electrolyte balance.&nbsp; <strong>&nbsp;</strong></p><p>Amoxicillin crystalluria, in some cases leading to renal failure, has been observed (see <em>Warnings and Precautions</em>).</p><p>&nbsp;</p><p><em>AUGMENTIN</em><strong><em> </em></strong>can<strong><em> </em></strong>be removed from the circulation by haemodialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>ATC Code <!--[if supportFields]><span style='mso-element:field-begin'></span><span
style='mso-spacerun:yes'> </span>DOCVARIABLE
vault_nd_a2bfe13e-ad6e-4a9e-a4d8-b3d02efb7535 \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p>Anatomical Therapeutic Chemical (ATC) code: J01CR02.</p><p>Pharmacotherapeutic group: Combinations of penicillins, incl. beta-lactamase inhibitors.</p><p>Resistance to many antibiotics is caused by bacterial enzymes which destroy the antibiotic before it can act on the pathogen. The clavulanate in <em>AUGMENTIN</em> suspension anticipates this defence mechanism by blocking the beta-lactamase enzymes, thus rendering the organisms sensitive to amoxicillin&#39;s rapid bactericidal effect at concentrations readily attainable in the body.&nbsp;</p><p>Clavulanate by itself has little antibacterial activity; however, in association with amoxicillin as <em>AUGMENTIN</em> it produces an antibiotic agent of broad spectrum with wide application in hospital and general practice.</p><p><strong>Pharmacodynamic Effects&nbsp; </strong></p><p>In the list below, organisms are categorised according to their <em>in vitro </em>susceptibility to</p><p><em>AUGMENTIN</em>.</p><table border="0" cellspacing="0" cellpadding="0" align="left" style="width:576px"><tbody><tr><td style="vertical-align:top"><p><strong><em>In vitro</em> susceptibility of micro-organisms to <em>AUGMENTIN</em></strong></p><p>&nbsp;</p><p>Where clinical efficacy of Augmentin has been demonstrated in clinical trials this is indicated with an asterisk (*).</p><p>&nbsp;</p><p>Organisms that do not produce beta-lactamase are identified (with <sup>&dagger;</sup>).&nbsp; If an isolate is susceptible to amoxicillin, it can be considered susceptible to <em>AUGMENTIN. </em></p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Commonly susceptible species</strong></p></td></tr><tr><td style="vertical-align:top"><p><u>Gram-positive aerobes:</u></p><p><em>Bacillius anthracis </em></p><p><em>Enterococcus faecalis </em></p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:575px"><tbody><tr><td style="vertical-align:bottom"><p><em>Listeria monocytogenes </em></p><p><em>Nocardia asteroides </em></p><p><em>Streptococcus pyogenes*</em><sup>&dagger;</sup><em> </em></p><p><em>Streptococcus agalactiae*</em><sup>&dagger;</sup><em> </em></p><p><em>Streptococcus</em> spp. (other beta-hemolytic)<em> *</em><sup>&dagger;</sup></p><p><em>Staphylococcus aureus</em> (methicillin susceptible)*</p><p><em>Staphylococcus saprophyticus</em> (methicillin susceptible)</p><p>Coagulase negative staphylococcus (methicillin susceptible)&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><u>Gram-negative aerobes:</u></p><p><em>Bordetella pertussis </em></p><p><em>Haemophilus influenzae* </em></p><p><em>Haemophilus parainfluenzae</em></p><p><em>Helicobacter pylori </em></p><p><em>Moraxella catarrhalis* </em></p><p><em>Neisseria gonorrhoeae<sup> </sup></em></p><p><em>Pasteurella multocida </em></p><p><em>Vibrio cholerae</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Other:</u></p><p><em>Borrelia burgdorferi<sup> </sup></em></p><p><em>Leptospira ictterohaemorrhagiae </em></p><p><em>Treponema pallidum</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Gram positive anaerobes:</u></p><p><em>Clostridium </em>spp.</p><p><em>Peptococcus niger </em></p><p><em>Peptostreptococcus magnus </em></p><p><em>&nbsp;</em></p><p><em>Peptostreptococcus micros</em></p><p><em>&nbsp;</em></p><p><em>Peptostreptococcus</em> spp.</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:575px"><tbody><tr><td style="vertical-align:top"><p><u>Gram-negative anaerobes:</u></p><p><em>Bacteroides fragilis Bacteroides</em> spp.</p><p><em>Capnocytophaga</em> spp.</p><p><em>Eikenella corrodens </em></p><p><em>Fusobacterium nucleatum </em></p><p><em>Fusobacterium</em> spp.</p><p><em>Porphyromonas</em> spp.</p><p><em>Prevotella</em> spp.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Species for which acquired resistance may be a problem</strong></p></td></tr><tr><td style="vertical-align:top"><p><u>Gram-negative aerobes:</u></p><p><em>Escherichia coli* </em></p><p><em>Klebsiella oxytoca Klebsiella pneumoniae* </em></p><p><em>Klebsiella</em> spp.</p><p><em>Proteus mirabilis </em></p><p><em>Proteus vulgaris Proteus</em> spp.</p><p><em>Salmonella</em> spp.</p><p>Shigella spp.&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><u>Gram-positive aerobes:</u></p><p><em>Corynebacterium</em> spp.<sup> </sup></p><p><em>Enterococcus faecium&nbsp; </em></p></td></tr><tr><td style="vertical-align:bottom"><p><em>Streptococcus pneumoniae*</em><sup>&dagger;<em> </em></sup></p><p>Viridans group streptococcus</p><p>&nbsp;</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Inherently resistant organisms</strong></p></td></tr><tr><td style="vertical-align:top"><p><u>Gram-negative aerobes:</u></p><p><em>Acinetobacter</em> spp. <em>Citrobacter freundii </em></p><p><em>Enterobacter</em> spp.</p><p><em>Hafnia alvei </em></p><p><em>Legionella pneumophila </em></p><p><em>Morganella morganii </em></p><p><em>Providencia </em>spp.</p><p><em>Pseudomonas</em> spp.</p><p><em>Serratia</em> spp.</p><p><em>Stenotrophomas maltophilia </em></p><p><em>Yersinia enterolitica</em></p></td></tr><tr><td style="vertical-align:top"><p><u>Others:</u></p><p><em>Chlamydia pneumoniae </em></p><p><em>Chlamydia psittaci Chlamydia</em> spp.&nbsp;</p><p><em>Coxiella burnetti </em></p><p><em>Mycoplasma </em>spp.</p></td></tr></tbody></table><p>&nbsp;</p><p>Infections caused by amoxicillin-susceptible organisms are amenable to <em>AUGMENTIN</em> treatment due to its amoxicillin content. Mixed infections caused by amoxicillin susceptible organisms in conjunction with <em>AUGMENTIN</em>-susceptible beta-lactamase producing organisms may therefore be treated with <em>AUGMENTIN.</em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Absorption: </strong></p><p>&nbsp;</p><p>The two components of <em>AUGMENTIN</em><strong> </strong>suspension<strong><em> </em></strong>228 mg/5 mL and 457 mg/5 mL, amoxicillin and clavulanate,<strong><em> </em></strong>are each fully dissociated in aqueous solution at physiological pH.&nbsp; Both components are rapidly and well absorbed by the oral route of administration.&nbsp; Absorption of <em>AUGMENTIN</em><strong> </strong>is optimised when taken at the start of a meal.</p><p>&nbsp;</p><p>The mean AUC values for amoxicillin are essentially the same following twice a day dosing with the <em>AUGMENTIN</em><strong> </strong>875/125 mg tablet or three times a day dosing with the <em>AUGMENTIN</em><strong> </strong>500/125 mg tablet, in adults.&nbsp; No differences between the 875 mg twice<strong><em> </em></strong>daily and 500 mg three times daily dosing regimes are seen when comparing the amoxicillin T1/2, or Cmax after normalisation for the different doses of amoxicillin administered.&nbsp; Similarly, no differences are seen for the clavulanate T1/2, Cmax or AUC values after appropriate dose normalisation.</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The time of dosing of <em>AUGMENTIN</em><strong> </strong>relative to the start of a meal has no marked effects on the pharmacokinetics of amoxicillin in adults.&nbsp; In a study of the <em>AUGMENTIN</em> 875/125 mg tablet, the time of dosing relative to ingestion of a meal had a marked effect on the pharmacokinetics of clavulanate.&nbsp; For clavulanate AUC and Cmax, the highest mean values and smallest inter-subject variabilities were achieved by administering <em>AUGMENTIN</em> at the start of a meal, compared to the fasting state or 30 or 150 minutes after the start of a meal.</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The mean Cmax, Tmax, T1/2 and AUC values for amoxicillin and clavulanate are given below for an 875 mg/125 mg dose of amoxicillin /clavulanic acid administered at the start of a meal.</p><p>&nbsp;</p><p>Mean Pharmacokinetic Parameters</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:group
 id="Group_x0020_22184" o:spid="_x0000_s1038" style='width:363.45pt;height:.7pt;
 mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
 coordsize="46156,91" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:shape id="Shape_x0020_25162" o:spid="_x0000_s1039" style='position:absolute;
  width:13718;height:91;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="1371854,9144" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l1371854,r,9144l,9144,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:stroke miterlimit="83231f" joinstyle="miter"/>
  <v:path arrowok="t" textboxrect="0,0,1371854,9144"/>
 </v:shape><v:shape id="Shape_x0020_25163" o:spid="_x0000_s1040" style='position:absolute;
  left:13719;width:92;height:91;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="9144,9144" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m,l9144,r,9144l,9144,,e" fillcolor="black" stroked="f" strokeweight="0">
  <v:stroke miterlimit="83231f" joinstyle="miter"/>
  <v:path arrowok="t" textboxrect="0,0,9144,9144"/>
 </v:shape><v:shape id="Shape_x0020_25164" o:spid="_x0000_s1041" style='position:absolute;
  left:13811;width:5395;height:91;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="539496,9144" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m,l539496,r,9144l,9144,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:stroke miterlimit="83231f" joinstyle="miter"/>
  <v:path arrowok="t" textboxrect="0,0,539496,9144"/>
 </v:shape><v:shape id="Shape_x0020_25165" o:spid="_x0000_s1042" style='position:absolute;
  left:19206;width:91;height:91;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="9144,9144" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l9144,r,9144l,9144,,e" fillcolor="black" stroked="f" strokeweight="0">
  <v:stroke miterlimit="83231f" joinstyle="miter"/>
  <v:path arrowok="t" textboxrect="0,0,9144,9144"/>
 </v:shape><v:shape id="Shape_x0020_25166" o:spid="_x0000_s1043" style='position:absolute;
  left:19297;width:6142;height:91;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="614172,9144" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,l614172,r,9144l,9144,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:stroke miterlimit="83231f" joinstyle="miter"/>
  <v:path arrowok="t" textboxrect="0,0,614172,9144"/>
 </v:shape><v:shape id="Shape_x0020_25167" o:spid="_x0000_s1044" style='position:absolute;
  left:25439;width:91;height:91;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="9144,9144" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l9144,r,9144l,9144,,e" fillcolor="black" stroked="f" strokeweight="0">
  <v:stroke miterlimit="83231f" joinstyle="miter"/>
  <v:path arrowok="t" textboxrect="0,0,9144,9144"/>
 </v:shape><v:shape id="Shape_x0020_25168" o:spid="_x0000_s1045" style='position:absolute;
  left:25530;width:6221;height:91;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="622097,9144" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m,l622097,r,9144l,9144,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:stroke miterlimit="83231f" joinstyle="miter"/>
  <v:path arrowok="t" textboxrect="0,0,622097,9144"/>
 </v:shape><v:shape id="Shape_x0020_25169" o:spid="_x0000_s1046" style='position:absolute;
  left:31751;width:91;height:91;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="9144,9144" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m,l9144,r,9144l,9144,,e" fillcolor="black" stroked="f" strokeweight="0">
  <v:stroke miterlimit="83231f" joinstyle="miter"/>
  <v:path arrowok="t" textboxrect="0,0,9144,9144"/>
 </v:shape><v:shape id="Shape_x0020_25170" o:spid="_x0000_s1047" style='position:absolute;
  left:31842;width:7026;height:91;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="702564,9144" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m,l702564,r,9144l,9144,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:stroke miterlimit="83231f" joinstyle="miter"/>
  <v:path arrowok="t" textboxrect="0,0,702564,9144"/>
 </v:shape><v:shape id="Shape_x0020_25171" o:spid="_x0000_s1048" style='position:absolute;
  left:38868;width:91;height:91;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="9144,9144" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m,l9144,r,9144l,9144,,e" fillcolor="black" stroked="f" strokeweight="0">
  <v:stroke miterlimit="83231f" joinstyle="miter"/>
  <v:path arrowok="t" textboxrect="0,0,9144,9144"/>
 </v:shape><v:shape id="Shape_x0020_25172" o:spid="_x0000_s1049" style='position:absolute;
  left:38959;width:7197;height:91;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="719633,9144" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQAdUSZNxAAAAN4AAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9Bi8Iw
FITvgv8hPMGbpha2K9UoIgjC4kHXi7dH82yrzUtpUq3+eiMIHoeZ+YaZLztTiRs1rrSsYDKOQBBn
VpecKzj+b0ZTEM4ja6wsk4IHOVgu+r05ptreeU+3g89FgLBLUUHhfZ1K6bKCDLqxrYmDd7aNQR9k
k0vd4D3ATSXjKEqkwZLDQoE1rQvKrofWKFjTdHtK2iM++OntxbS7/C/RSg0H3WoGwlPnv+FPe6sV
xD+T3xjed8IVkIsXAAAA//8DAFBLAQItABQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAAAAAAAAA
AAAAAAAAAABbQ29udGVudF9UeXBlc10ueG1sUEsBAi0AFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsA
AAAAAAAAAAAAAAAAHwEAAF9yZWxzLy5yZWxzUEsBAi0AFAAGAAgAAAAhAB1RJk3EAAAA3gAAAA8A
AAAAAAAAAAAAAAAABwIAAGRycy9kb3ducmV2LnhtbFBLBQYAAAAAAwADALcAAAD4AgAAAAA=
" path="m,l719633,r,9144l,9144,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:stroke miterlimit="83231f" joinstyle="miter"/>
  <v:path arrowok="t" textboxrect="0,0,719633,9144"/>
 </v:shape><w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="485" height="1" src="file:///C:/Users/aa630244/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1026" type="#_x0000_t75" style='width:363.45pt;height:.7pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p><p>Drug Dose&nbsp; Cmax Tmax* AUC T1/2 Administration (mg) (mg/L) (hours) (mg.h/L) (hours)</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>AUGMENTIN</em><strong> </strong>1g &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Amoxicillin &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 875&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 12.4 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1.5 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 29.9 1.36</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Clavulanate &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 125&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3.3 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1.3 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 6.88 0.92</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:group
 id="Group_x0020_22185" o:spid="_x0000_s1026" style='width:364.15pt;height:.7pt;
 mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
 coordsize="46247,91" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:shape id="Shape_x0020_25184" o:spid="_x0000_s1027" style='position:absolute;
  width:13809;height:91;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="1380998,9144" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l1380998,r,9144l,9144,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:stroke miterlimit="83231f" joinstyle="miter"/>
  <v:path arrowok="t" textboxrect="0,0,1380998,9144"/>
 </v:shape><v:shape id="Shape_x0020_25185" o:spid="_x0000_s1028" style='position:absolute;
  left:13719;width:92;height:91;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="9144,9144" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,l9144,r,9144l,9144,,e" fillcolor="black" stroked="f" strokeweight="0">
  <v:stroke miterlimit="83231f" joinstyle="miter"/>
  <v:path arrowok="t" textboxrect="0,0,9144,9144"/>
 </v:shape><v:shape id="Shape_x0020_25186" o:spid="_x0000_s1029" style='position:absolute;
  left:13811;width:5486;height:91;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="548640,9144" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQDwd7qfxwAAAN4AAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9Pa8JA
FMTvBb/D8gRvdWNoQ4yuIhaxUHow/jk/s88kmH0bsqum375bKHgcZuY3zHzZm0bcqXO1ZQWTcQSC
uLC65lLBYb95TUE4j6yxsUwKfsjBcjF4mWOm7YN3dM99KQKEXYYKKu/bTEpXVGTQjW1LHLyL7Qz6
ILtS6g4fAW4aGUdRIg3WHBYqbGldUXHNb0ZBeUva+Pj2MU033/XplOtzsj18KTUa9qsZCE+9f4b/
259aQfw+SRP4uxOugFz8AgAA//8DAFBLAQItABQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAAAAA
AAAAAAAAAAAAAABbQ29udGVudF9UeXBlc10ueG1sUEsBAi0AFAAGAAgAAAAhAFr0LFu/AAAAFQEA
AAsAAAAAAAAAAAAAAAAAHwEAAF9yZWxzLy5yZWxzUEsBAi0AFAAGAAgAAAAhAPB3up/HAAAA3gAA
AA8AAAAAAAAAAAAAAAAABwIAAGRycy9kb3ducmV2LnhtbFBLBQYAAAAAAwADALcAAAD7AgAAAAA=
" path="m,l548640,r,9144l,9144,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:stroke miterlimit="83231f" joinstyle="miter"/>
  <v:path arrowok="t" textboxrect="0,0,548640,9144"/>
 </v:shape><v:shape id="Shape_x0020_25187" o:spid="_x0000_s1030" style='position:absolute;
  left:19206;width:91;height:91;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="9144,9144" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,l9144,r,9144l,9144,,e" fillcolor="black" stroked="f" strokeweight="0">
  <v:stroke miterlimit="83231f" joinstyle="miter"/>
  <v:path arrowok="t" textboxrect="0,0,9144,9144"/>
 </v:shape><v:shape id="Shape_x0020_25188" o:spid="_x0000_s1031" style='position:absolute;
  left:19297;width:6233;height:91;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="623316,9144" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m,l623316,r,9144l,9144,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:stroke miterlimit="83231f" joinstyle="miter"/>
  <v:path arrowok="t" textboxrect="0,0,623316,9144"/>
 </v:shape><v:shape id="Shape_x0020_25189" o:spid="_x0000_s1032" style='position:absolute;
  left:25439;width:91;height:91;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="9144,9144" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m,l9144,r,9144l,9144,,e" fillcolor="black" stroked="f" strokeweight="0">
  <v:stroke miterlimit="83231f" joinstyle="miter"/>
  <v:path arrowok="t" textboxrect="0,0,9144,9144"/>
 </v:shape><v:shape id="Shape_x0020_25190" o:spid="_x0000_s1033" style='position:absolute;
  left:25530;width:6313;height:91;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="631241,9144" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,l631241,r,9144l,9144,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:stroke miterlimit="83231f" joinstyle="miter"/>
  <v:path arrowok="t" textboxrect="0,0,631241,9144"/>
 </v:shape><v:shape id="Shape_x0020_25191" o:spid="_x0000_s1034" style='position:absolute;
  left:31751;width:91;height:91;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="9144,9144" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m,l9144,r,9144l,9144,,e" fillcolor="black" stroked="f" strokeweight="0">
  <v:stroke miterlimit="83231f" joinstyle="miter"/>
  <v:path arrowok="t" textboxrect="0,0,9144,9144"/>
 </v:shape><v:shape id="Shape_x0020_25192" o:spid="_x0000_s1035" style='position:absolute;
  left:31842;width:7117;height:91;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="711708,9144" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,l711708,r,9144l,9144,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:stroke miterlimit="83231f" joinstyle="miter"/>
  <v:path arrowok="t" textboxrect="0,0,711708,9144"/>
 </v:shape><v:shape id="Shape_x0020_25193" o:spid="_x0000_s1036" style='position:absolute;
  left:38868;width:91;height:91;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="9144,9144" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,l9144,r,9144l,9144,,e" fillcolor="black" stroked="f" strokeweight="0">
  <v:stroke miterlimit="83231f" joinstyle="miter"/>
  <v:path arrowok="t" textboxrect="0,0,9144,9144"/>
 </v:shape><v:shape id="Shape_x0020_25194" o:spid="_x0000_s1037" style='position:absolute;
  left:38959;width:7288;height:91;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="728777,9144" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l728777,r,9144l,9144,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:stroke miterlimit="83231f" joinstyle="miter"/>
  <v:path arrowok="t" textboxrect="0,0,728777,9144"/>
 </v:shape><w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="485" height="1" src="file:///C:/Users/aa630244/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1025" type="#_x0000_t75" style='width:364.15pt;height:.7pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p><p>*Median values</p><p>Amoxicillin serum concentrations achieved with <em>AUGMENTIN</em> are similar to those produced by the oral administration of equivalent doses of amoxicillin alone.</p><p><strong>&nbsp;</strong></p><p>Distribution<!--[if supportFields]><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_d7068f66-f60f-485f-a1c8-909e4ef0ffa3 \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The pharmacokinetics of the two components of <em>AUGMENTIN</em> are closely matched. Both clavulanate and amoxicillin have low levels of serum binding; about 70% remains free in the serum.</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Doubling the dosage of <em>AUGMENTIN</em> approximately doubles the serum levels achieved.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No further information of relevance.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>AUGMENTIN dry powder for suspension contains<strong><em> </em></strong>xanthan gum,</p><p>hydroxypropylmethylcellulose, colloidal silica, succinic acid, silicon dioxide, aspartame and dry flavours (raspberry, orange &ldquo;1&rdquo;, orange &ldquo;2&rdquo;and golden syrup).</p><p>For important information about some of these excipients see<em> Special Warnings and Precautions for use.</em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None known.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The expiry date is indicated on the packaging.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not take after the expiry date shown on the pack.</p><p>The dry powder should be stored in unopened containers in a dry place at below 25&deg;C.</p><p>Once reconstituted, the suspension must be stored in a refrigerator (2&deg;C to 8&deg;C) and used within 7 days. Do not freeze.<em> </em>(see also<em> </em>. Special Precautions for disposal &lt;and other handling).<em> </em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>AUGMENTIN for suspension in bottles</em><!--[if supportFields]><i style='mso-bidi-font-style:
normal'><span style='font-weight:normal'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_1ed4acc8-a8bd-49dc-94f8-9ab0d14c6700 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></i><![endif]--><em>&nbsp;</em><!--[if supportFields]><i
style='mso-bidi-font-style:normal'><span style='font-weight:normal'><span
style='mso-element:field-end'></span></span></i><![endif]--></p><p>Clear glass bottles containing powder for reconstitution. Bottles may be supplied with either an aluminium screw cap with a ring seal or a plastic child-resistant cap with a removable foil-backed seal on the bottle. Fill-lines are indicated on the bottle label. Bottles may be supplied with a plastic dosing device.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>AUGMENTIN suspension in bottles</em><!--[if supportFields]><i style='mso-bidi-font-style:
normal'><span style='font-weight:normal'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_a9d573b1-519b-46e9-af85-b014c39babc5 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></i><![endif]--><em>&nbsp;</em><!--[if supportFields]><i
style='mso-bidi-font-style:normal'><span style='font-weight:normal'><span
style='mso-element:field-end'></span></span></i><![endif]--></p><p>For bottles with aluminium screw caps, check the cap ring seal is intact before using. Alternatively, for bottles with a plastic child-resistant cap, check the foil-backed bottle seal is intact before using.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; At time of use, the dry powder should be reconstituted to form an oral suspension, as detailed below:</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Invert and shake bottle to loosen powder.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Add volume of water (indicated below). Invert and shake well</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Alternatively, fill the bottle with water to just below the mark on bottle label.</p><p>Invert and shake well, then top up with water to the mark. Invert and shake again.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allow to stand for 5 minutes to ensure full dispersion.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shake well before taking each dose.</p><p>&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:455px"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong><em>AUGMENTIN suspension 228 mg/5 mL </em></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Fill Weight (g) </strong></p><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Volume of water to be added to reconstitute</strong> (mL)</p></td><td style="vertical-align:top"><p><strong>Final volume of reconstituted oral suspension</strong> (mL)</p></td></tr><tr><td style="vertical-align:top"><p>7.7&nbsp;</p></td><td style="vertical-align:top"><p>64&nbsp;</p></td><td style="vertical-align:top"><p>70&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>15.4&nbsp;</p></td><td style="vertical-align:top"><p>128&nbsp;</p></td><td style="vertical-align:top"><p>140&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:455px"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong><em>AUGMENTIN suspension 457 mg/5 mL </em></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Fill Weight (g) </strong></p></td><td style="vertical-align:top"><p><strong>Volume of water to be added to reconstitute (mL) </strong></p></td><td style="vertical-align:top"><p><strong>Final volume of reconstituted oral suspension (mL) </strong></p></td></tr><tr><td style="vertical-align:top"><p>6.3&nbsp;</p></td><td style="vertical-align:top"><p>31&nbsp;</p></td><td style="vertical-align:top"><p>35&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>12.6&nbsp;</p></td><td style="vertical-align:top"><p>62&nbsp;</p></td><td style="vertical-align:top"><p>70&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>25.2&nbsp;</p></td><td style="vertical-align:top"><p>124&nbsp;</p></td><td style="vertical-align:top"><p>140&nbsp;</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>A plastic dosing device may be supplied with the pack which can be used to measure the dose accurately.</p><p>Discard any unused suspension after 7 days.</p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.<strong> </strong>&nbsp;</p><p>&nbsp;</p><p><strong>Not all presentations are available in every country.</strong></p><p>&copy;2023 GSK group of companies, All Rights Reserved.</p><p>Trademarks are owned by or licensed to the GSK group of companies.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Manufactured by: 
Glaxo Wellcome Production*, Mayenne, France 
Packed by & MAH: 
Glaxo Saudi Arabia Ltd.*, Jeddah, KSA 
*Member of the GSK group of companies. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Version number: GDS29/IPI17 
Date of issue: 07 September 2023

            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>